Inactivation of Pleiotropic Regulator 1 reveals p53-dependent Control of Cell Proliferation and Apoptosis by the Pso4-complex

Inaugural-Dissertation
zur
Erlangung des Doktorgrades
der Mathematisch-Naturwissenschaftlichen Fakultät
der Universität zu Köln

vorgelegt von
André Kleinridders
aus Krefeld
Köln 2007
Berichterstatter:  Prof. Dr. Jens Brüning
                 Prof. Dr. Thomas Langer

Tag der mündlichen Prüfung: __________ 09. Juli 2007 ______________
Für Tina
„Darin besteht das Wesen der Wissenschaft. Zuerst denkt man an etwas, das wahr sein könnte. Dann sieht man nach, ob es der Fall ist und im allgemeinen ist es nicht der Fall."

# Table of contents

Table of contents

Table of figures ................................................................. IV

List of tables ........................................................................ VI

Abbreviations ....................................................................... VII

1 Introduction ....................................................................... 1

1.1 PLRG-1, an evolutionary conserved component of the spliceosome 1
1.2 Regulation of pre-mRNA splicing ................................................. 2
1.3 Role of PLRG-1 in DNA repair ......................................................... 6
1.4 DNA damage leads to cell cycle arrest ......................................... 9
1.5 Regulation of apoptosis in DNA damage and repair .................... 14
1.6 Involvement of the Bcl-2 family in the regulation of apoptosis ...... 16
1.7 Objectives ............................................................................. 19

2 Materials and Methods .................................................. 20

2.1 Chemicals and antibodies .......................................................... 20
2.2 Molecular biology ...................................................................... 22

  2.2.1 Competent *E. coli* and isolation of plasmid DNA ............... 22
  2.2.2 Construction of targeting vectors ......................................... 22
  2.2.3 TA-cloning .......................................................................... 24
  2.2.4 Generation of gene replacement vectors .............................. 24
  2.2.5 Isolation of genomic DNA .................................................... 24
  2.2.6 DNA electrophoresis ............................................................. 25
  2.2.7 Pulsed-field gel electrophoresis ........................................... 25
  2.2.8 DNA sequencing ................................................................ 26
  2.2.9 Quantification of DNA .......................................................... 26
  2.2.10 PCR .................................................................................. 26
  2.2.11 RT-PCR and quantitative Real-Time PCR .......................... 29
  2.2.12 DNA hybridization ............................................................. 31
  2.2.13 Northern Blot and RNA hybridization ............................... 31

2.3 Cell culture .......................................................................... 32

  2.3.1 Primary embryonic fibroblast (EF) culture ............................... 32
  2.3.2 Embryonic stem (ES) cell culture .......................................... 33
  2.3.3 HTN-Cre-mediated deletion *in vitro* ..................................... 34
  2.3.4 Cell cycle analysis ................................................................. 34
  2.3.5 Cell cycle analysis using fluorescence-activated cell sorter (FACS) analysis ................................................................. 34
  2.3.6 *³*H-thymidine incorporation .................................................. 35
2.3.7 Analysis of apoptosis ................................................................. 35
2.3.8 DNA double-strand breaks after UV-treatment ......................... 36
2.3.9 Immunofluorescence ................................................................. 36
2.3.10 RNA interference (RNAi) .......................................................... 37

2.4 Biochemistry .................................................................................. 37
2.4.1 Protein extraction from tissue....................................................... 37
2.4.2 Protein extraction from cells ......................................................... 37
2.4.3 Nuclear and cytoplasmic protein extraction ................................ 38
2.4.4 Immunoprecipitation .................................................................. 38
2.4.5 Western Blot ............................................................................... 39
2.4.6 Immunohistochemistry ............................................................... 40

2.5 Statistical methods ......................................................................... 40
2.6 Animal Care .................................................................................... 41
2.6.1 Mouse experiments ..................................................................... 41
2.6.2 Mice ......................................................................................... 41

3 Results............................................................................................... 42
3.1 Murine expression pattern of PLRG-1.............................................. 43
3.2 Generation of a conventional PLRG-1 gene replacement vector..... 44
3.3 Analysis of PLRG-1\(\Delta^+/\) mice ....................................................... 46
3.4 PLRG-1\(\Delta/\Delta\) mice are embryonic lethal ....................................... 47
3.5 Generation of a conditional PLRG-1 gene replacement vector ...... 50
3.6 Inactivation of PLRG-1 in mouse embryonic fibroblasts blocks cell proliferation ................................................................. 53
3.7 PLRG-1 deficiency prevents S-phase entry ...................................... 55
3.8 PLRG-1 deficiency increases p53 expression and induces apoptosis .................................................................................. 57
3.9 No evidence for altered splicing in PLRG1-deficient MEFs ............ 60
3.10 PLRG-1-deficient MEFs exhibit no spontaneously detectable DNA double-strand breaks .......................................................... 62
3.11 PLRG-1 deficiency results in enhanced γ-H2AX phosphorylation . 63
3.12 Conditional inactivation of PLRG-1 in heart and skeletal muscle .. 64
3.13 Conditional inactivation of PLRG-1 in heart results in dilated cardiomyopathy due to increased cardiomyocyte apoptosis .......... 66
3.14 Conditional inactivation of PLRG-1 in the central nervous system of mice results in early postnatal lethality .............................. 68
3.15 Neuron-restricted PLRG-1 deficiency results in massive neuronal apoptosis ................................................................. 69
3.16 Interaction of the nuclear CDC5L-PLRG-1 complex with the p53 phosphatase WIP1 is disrupted in the absence of PLRG-1........... 71
3.17 Rescue of the apoptotic PLRG-1 phenotype by knockdown of p5373

4 Discussion ........................................................................................ 77
4.1 Essential role for PLRG-1 in the development of the preimplantation murine embryo ................................................................. 77
4.2 Disruption of other splicing factors and their effects .................. 78
4.3 Function of PLRG-1 orthologues ................................................. 79
4.4 PLRG-1 in control of cell cycle and apoptosis .............................. 80
4.5 Impaired DNA damage repair as a consequence of PLRG-1 deficiency ................................................................. 83
4.6 Proposed model for PLRG-1, linking DNA repair, control of cell cycle progression and apoptosis via the Pso4-complex ............. 85

5 Summary ....................................................................................... 89

6 Zusammenfassung ........................................................................ 90

7 Kurzzusammenfassung ................................................................. 91

8 References .................................................................................... 92

9 Acknowledgements ...................................................................... 115

10 Versicherung ............................................................................. 116

11 Lebenslauf ................................................................................ 117
Table of figures

Figure 1.1: Schematic representation of splicing reaction.............................5
Figure 1.2: Schematic representation of the Pso4-complex in ICL repair....8
Figure 1.3: Schematic representation of DNA damage
checkpoint pathway...........................................................................................9
Figure 1.4: Schematic representation of the G1/S checkpoint....................11
Figure 1.5: Apoptosis signalling in response to p53 activation...............18
Figure 2.1: Schematic representation of semi-nested PCR method...........28
Figure 3.1: Ubiquitous expression of PLRG-1..............................................43
Figure 3.2: Conventional inactivation of the PLRG-1 gene......................46
Figure 3.3: Analysis of PLRG-1^{+/−} offspring..............................................47
Figure 3.4: Identification of genotype using semi-nested PCR...............49
Figure 3.5: Representative morphology of wild type and
PLRG-1-deficient embryos at ED1.5.................................................................50
Figure 3.6: Conditional inactivation of the PLRG-1 gene.........................52
Figure 3.7: Verification of PLRG-1 deletion in MEFs upon
HTNC treatment ...................................................................................................53
Figure 3.8: Growth rates and morphology of untreated or Cre-treated
wild type and PLRG-1^{floxflo} MEFs..................................................................55
Figure 3.9: FACS analysis of serum (FCS)-stimulated cell cycle
progression in control and PLRG-1-deficient MEFs......................................56
Figure 3.10: 3H-thymidine incorporation of wild type and
PLRG-1-deficient MEFs......................................................................................57
Figure 3.11: Western blot analysis of HTNC-treated wild type (WT) and
PLRG-1^{floxflo} MEF (KO)..................................................................................59
Figure 3.12: TUNEL analysis of wild type and PLRG-1-deficient MEFs.....60
Figure 3.13: Splicing in PLRG-1-deficient MEFs is unaltered..................61
Figure 3.14: Pulse-field gel electrophoresis of PLRG-1^{floxflo} (control)
and PLRG-1-deficient MEFs (KO)......................................................................62
Figure 3.15: Analysis of γ-H2AX phosphorylation in untreated
and HTNC-treated PLRG-1^{floxflo} MEFs.............................................................63
Figure 3.16: Heart-restricted PLRG-1 deficiency in PLRG-1^{mus} mice........65
Table of figures

Figure 3.17: Survival rate of control and PLRG-1\(^{Δ\text{mus}}\) mice..........................65
Figure 3.18: Heart-phenotype of PLRG-1\(^{Δ\text{mus}}\) mice.............................................66
Figure 3.19: Histological analysis of control- and PLRG-1\(^{Δ\text{mus}}\)-hearts at
the age of 24 days..................................................................................................67
Figure 3.20: Western blot analysis of control (C) and
PLRG-1\(^{Δ\text{mus}}\)-(KO) hearts..................................................................................68
Figure 3.21: Survival rate of control and PLRG-1\(^{Δ\text{CNS}}\) mice..............................69
Figure 3.22: Analysis of neuron-restricted recombination of the
PLRG-1\(^{\text{flox/flox}}\) allele............................................................................................69
Figure 3.23: Immunohistochemical analysis of brains dissected from
3-day-old control and PLRG-1\(^{Δ\text{CNS}}\) mice.........................................................70
Figure 3.24: Western blot analysis of control (C) and PLRG-1\(^{Δ\text{CNS}}\) (KO)
hearts.........................................................................................................................71
Figure 3.25: CDC5L and WIP1 fail to form complexes in the nucleus of
PLRG-1-deficient MEFs..........................................................................................73
Figure 3.26: Rescue of the apoptotic PLRG-1 phenotype by
knockdown of p53.................................................................................................74
Figure 4.1: Schematic representation of G1/S-phase progression
and block....................................................................................................................81
Figure 4.2: Proposed model for novel integration of pre-mRNA
splicing components linking DNA repair, and control of cell cycle
progression and apoptosis via CDC5L-PLRG-1 interaction...............................87
List of tables

Table 2.1: Chemicals.........................................................................................................................20
Table 2.2: Oligonucleotides used for generation of gene replacement vectors and probes for Southern and Northern Blot......................................................22
Table 2.3: List of primers used for genotyping..................................................................................28
Table 2.4: List of oligonucleotides used for amplification of cDNA..............................................30
Table 2.5: List of probes used for quantitative Real-Time PCR..........................................................30
Table 2.6: Antibodies used for biochemical studies...........................................................................39
Table 3.1: Genotype analysis of PLRG-1^+/Δ^-intercross offspring based on a semi-nested PCR approach...........................................................................................................48
Table 3.2: Genotype analysis of mice obtained from breedings of PLRG-1^flox/flox^ mice with PLRG-1^flox/+^ MCKCre mice.........................................................................................................64
Table 3.3: Genotype analysis of mice obtained from breedings of PLRG-1^flox/flox^ mice with PLRG-1^flox/+^ SynCre mice..............................................................................................................68
## Abbreviations

<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Definition</th>
</tr>
</thead>
<tbody>
<tr>
<td>A</td>
<td>adenosine</td>
</tr>
<tr>
<td>aa</td>
<td>amino acid</td>
</tr>
<tr>
<td>AP</td>
<td>apurine / apyrimidine</td>
</tr>
<tr>
<td>BAC</td>
<td>bacterial artificial chromosome</td>
</tr>
<tr>
<td>bp</td>
<td>base pairs</td>
</tr>
<tr>
<td>BSA</td>
<td>bovine serum albumin</td>
</tr>
<tr>
<td>C</td>
<td>control</td>
</tr>
<tr>
<td>°C</td>
<td>temperature in degrees celsius</td>
</tr>
<tr>
<td>cDNA</td>
<td>complementary DNA</td>
</tr>
<tr>
<td>CO₂</td>
<td>carbon dioxide</td>
</tr>
<tr>
<td>cps</td>
<td>counts per second</td>
</tr>
<tr>
<td>Cre</td>
<td>causes recombination, recombinase from phage P1</td>
</tr>
<tr>
<td>C-terminal</td>
<td>carboxy-terminal</td>
</tr>
<tr>
<td>d</td>
<td>day/s</td>
</tr>
<tr>
<td>DEPC</td>
<td>diethylpyrocarbonate</td>
</tr>
<tr>
<td>DNA</td>
<td>desoxyribonucleic acid</td>
</tr>
<tr>
<td>dNTP</td>
<td>desoxyribonucleotide-triphosphate</td>
</tr>
<tr>
<td>DMEM</td>
<td>Dulbecco’s modified Eagle medium</td>
</tr>
<tr>
<td>DMSO</td>
<td>Dimethyl sulfoxide</td>
</tr>
<tr>
<td>DTT</td>
<td>1,4-Dithio- DL-threitol</td>
</tr>
<tr>
<td>E. coli</td>
<td><em>Escherichia coli</em></td>
</tr>
<tr>
<td>ECL</td>
<td>enhanced chemiluminescence</td>
</tr>
<tr>
<td>ED</td>
<td>embryonic day</td>
</tr>
<tr>
<td>EDTA</td>
<td>ethylene-diaminetetraacetic acid</td>
</tr>
<tr>
<td>EF</td>
<td>embryonic fibroblasts</td>
</tr>
<tr>
<td>ES</td>
<td>embryonic stem cells</td>
</tr>
<tr>
<td>EtBr</td>
<td>ethidiumbromide</td>
</tr>
<tr>
<td>EtOH</td>
<td>ethanol</td>
</tr>
<tr>
<td>F</td>
<td>farad</td>
</tr>
<tr>
<td>FACS</td>
<td>fluorescence activated cell sorting</td>
</tr>
<tr>
<td>FCS</td>
<td>foetal calf serum</td>
</tr>
</tbody>
</table>
Abbreviations

flox  lox P flanked
Flp  site-specific recombinase, product of yeast FLP1-gene
FRT  Flp recombination target
g  gram
G  guanosine
GANC  ganciclovir
G418  geneticin sulfate
h  hour/s
HCl  Hydrogenchlorid
HEPES  N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid
HR  Homologous recombinant
HSV-tk  Herpes simplex virus-thymidine kinase
ICL  Interstrand crosslinks
LA  long arm of homology
LIF  leukaemia inhibitory factor
Kb  Kilobase pairs
KCl  potassium chloride
kD/kDa  kilodalton
loxP  recognition sequence for Cre (locus of x-ing over of phage P1)
M  molar
MCK  Muscle creatinine kinase
MgCl₂  magnesium chloride
min  minute
ml  milliliter
mM  millimolar
MMC  mitomycin C
µg  microgram
µl  microliter
µM  micromolar
NaCl  sodium chloride
NaF  sodium fluoride
NaOH  sodium hydroxide
Na₃O₄V  sodium orthovanadate
<table>
<thead>
<tr>
<th>Abbreviation</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>neo</td>
<td>neomycin resistance gene</td>
</tr>
<tr>
<td>N-terminal</td>
<td>amino-terminal</td>
</tr>
<tr>
<td>OD</td>
<td>optical density</td>
</tr>
<tr>
<td>OH</td>
<td>hydroxyl</td>
</tr>
<tr>
<td>PBS</td>
<td>Phosphate buffered saline</td>
</tr>
<tr>
<td>PCR</td>
<td>polymerase chain reaction</td>
</tr>
<tr>
<td>PFGE</td>
<td>pulsed-field gel electrophoresis</td>
</tr>
<tr>
<td>RNA</td>
<td>ribonucleic acid</td>
</tr>
<tr>
<td>rpm</td>
<td>revolutions per minute</td>
</tr>
<tr>
<td>RS</td>
<td>arginine/serine rich</td>
</tr>
<tr>
<td>RT</td>
<td>room temperature</td>
</tr>
<tr>
<td>s</td>
<td>second</td>
</tr>
<tr>
<td>SA</td>
<td>short arm of homology</td>
</tr>
<tr>
<td>SDS</td>
<td>sodium dodecyl sulfate</td>
</tr>
<tr>
<td>ss</td>
<td>single stranded</td>
</tr>
<tr>
<td>SSC</td>
<td>sodium chloride/ sodium citrate buffer</td>
</tr>
<tr>
<td>SYN</td>
<td>synapsin</td>
</tr>
<tr>
<td>T</td>
<td>thymidine</td>
</tr>
<tr>
<td>TAE</td>
<td>Tris-acetic acid-EDTA buffer</td>
</tr>
<tr>
<td>Taq</td>
<td>polymerase from Thermus aquaticus</td>
</tr>
<tr>
<td>TBE</td>
<td>Tris-acetic basic-EDTA buffer</td>
</tr>
<tr>
<td>T-DNA</td>
<td>transfer-DNA</td>
</tr>
<tr>
<td>TE</td>
<td>Tris-EDTA buffer</td>
</tr>
<tr>
<td>Tris</td>
<td>2-amino-2-(hydroxymethyl)-1,3-propandiole</td>
</tr>
<tr>
<td>TWEEN</td>
<td>polyoxethylene-sorbitan-monolaureate</td>
</tr>
<tr>
<td>U</td>
<td>unit</td>
</tr>
<tr>
<td>UV</td>
<td>ultraviolet</td>
</tr>
<tr>
<td>V</td>
<td>volt</td>
</tr>
<tr>
<td>WT</td>
<td>wild type</td>
</tr>
<tr>
<td>Y</td>
<td>pyrimidine</td>
</tr>
<tr>
<td>5´</td>
<td>five prime end of DNA sequences</td>
</tr>
<tr>
<td>3´</td>
<td>three prime end of DNA sequences</td>
</tr>
<tr>
<td>Δ</td>
<td>knockout/PLRG-1-deleted allele</td>
</tr>
</tbody>
</table>
1 Introduction

1.1 PLRG-1, an evolutionary conserved component of the spliceosome

Mammalian Pleiotropic Regulator (PLRG-) 1 is an essential component of the spliceosome. PLRG-1 belongs to a highly conserved family of seven WD40 domain containing proteins in eukaryotes (Ajuh et al., 2000; Ajuh et al., 2001). Founding members of this WD40-repeat protein family, PRL1 and PRL2, were first identified by T-DNA tagging in Arabidopsis thaliana (Nemeth et al., 1998). Mutation of Arabidopsis PRL1 confers hypersensitivity to glucose, sucrose and several plant hormones and results in transcriptional derepression of glucose and stress responsive genes (Nemeth et al., 1998). Whereas in plants the PRL genes are uniquely duplicated, in yeast, C. elegans and mammals there are only single orthologues of the Pleiotropic Regulator family which play important roles in the control of cellular homeostasis. siRNA-mediated knock-down of PLRG-1 (D1054.15) in C. elegans results in early embryonic lethality, whereas mutation of the yeast homologue YPL151c (Prp46) arrests cell proliferation causing a dual block in G1/S- and M-phase progression (Albers et al., 2003; Sonnichsen et al., 2005). Despite genetic studies of mutations, the exact regulatory function of PLRG-1 orthologues and the molecular mechanisms by which they integrate splicing and control cell proliferation so far remain elusive.

Human PLRG-1 has been initially identified as a subunit of spliceosomal complexes purified from HeLa nuclear extracts by coimmunoprecipitation with CDC5L (Ajuh et al., 2000). Later, it was observed that interaction between PLRG-1 and CDC5L is essential for pre-mRNA processing as peptides inhibiting complex formation of CDC5L with PLRG-1 efficiently block pre-mRNA splicing (Ajuh and Lamond, 2003). These studies also revealed that other proteins not directly implicated in regulation of pre-mRNA splicing, such as the cell cycle phosphatase PPM1D/WIP1, PP1-α and the DNA-dependent kinase (DDK)-α co-purified with the PLRG-1 containing CDC5L complex (Ajuh et al., 2000). These components also play a role in cell cycle regulation, apoptosis
and genome integrity. WIP1, a serine/threonine phosphatase, is a member of the PP2C family and was shown to be a negative regulator of p53 (Fiscella et al., 1997; Lu et al., 2004; Takekawa et al., 2000). PP1-α, another serine/threonine phosphatase, plays an important role in the control of cell cycle progression and apoptosis by interacting with retinoblastoma protein (Liu et al., 1999). The other complex component, DNA-dependent kinase DDK-α, a serine/threonine kinase, is activated by DNA association and plays a role in processes such as DNA double-strand break repair, telomere maintenance and gene transcription (Boulton and Jackson, 1996; Boulton and Jackson, 1998; Smith and Jackson, 1999; Taccioli et al., 1998).

Recently, the CDC5L-PLRG-1 complex was demonstrated to interact with the WRN protein, which is deficient in Werner syndrome and required for processing of DNA interstrand crosslinks (Zhang et al., 2005). In addition to pre-mRNA splicing, the CDC5L-PLRG-1 complex is thus possibly involved in DNA repair. Another known component of the nuclear CDC5L-PLRG-1 complex is the mammalian homologue Pso4/PRP19, which is essential both for pre-mRNA-splicing and UV-radiation mediated crosslink repair (Mahajan and Mitchell, 2003). These findings strongly suggest that the Pso4-CDC5L-PLRG-1 complex integrates pre-mRNA splicing and DNA-repair.

1.2 Regulation of pre-mRNA splicing

Most genes in eukaryotes are interrupted several times by intervening sequences, known as introns, which are transcribed into primary messenger RNA transcripts (pre-mRNA). For functional translation, these non-coding sequences have to be precisely excised, generating functional mRNAs. This task is performed by a ribonucleoprotein complex, called spliceosome. This complex consists of five small nuclear ribonucleoprotein (SnRNP) complexes U1, U2, U4, U5 and U6 and about 300 other non-snRNP proteins (Rappsilber et al., 2002; Zhou et al., 2002). The spliceosome orchestrates the precise excision of introns by several RNA-RNA, RNA-protein and protein-protein interactions. A key feature of correct splicing is the presence of a conserved 5´ and 3´ splice
site, a branch point region usually 20-40 nucleotides upstream of the 3´ splice site and a polypyrimidine tract in the intron (Reed 1989; Smith et al., 1989; Stephens and Schneider 1992).

For many years it was thought that the spliceosome assembles in a stepwise manner. First, U1 snRNP binds to the 5´ splice site, while the serine/arginine (SR) protein U2AF$^{65}$ binds the polypyrimidine tract and another SR protein U2AF$^{35}$ binds the 3´ splice site (Merendino et al., 1999; Wu et al., 1999; Zamore et al., 1992; Zorio and Blumenthal, 1999). This RNA-protein complex is known as the E-complex (Michaud and Reed, 1991). Then, U2 snRNP binds weakly to the pre-mRNA using the integral associated U2 snRNP protein SF3b (Hastings and Krainer, 2001). Next, U2 snRNP binds to the branchpoint region forming the A-complex, a process dependent on ATP (Furmen and Glitz, 1995; Kramer, 1996). Subsequently, the U4/U6/U5 tri-snRNP complex adheres to the 5´ splice site by interacting with Prp8 and the pre-mRNA in the presence of ATP, thereby generating the B-complex (Brown and Beggs, 1992; Umen and Guthrie, 1995; Umen and Guthrie, 1995). Exclusion of U1 and U4 snRNP leads to the active C-complex, which catalyzes the excision of introns (Fig. 1.1) (Jurica et al., 2004; Yean and Liu, 1991).

Recent findings suggest, that the spliceosome is partly preassembled (Nilsen 2002; Stevens et al., 2003). Upon complete assembly, the spliceosome undergoes dramatic conformational changes involving both its RNA and proteins prior to catalysis. These rearrangements result in the exclusion of two snRNPs, U1 and U4, and inclusion of new proteins, responsible for correct splicing reactions (Makarov et al., 2002; Staley and Guthrie, 1998) leading to the active complex.

The splicing reaction occurs in two steps by transesterification. First, the 2´OH group of the branchpoint adenosine performs a nucleophilic attack at the 5´ splice site, destroying the phosphodiesterbond and thereby generating a 2´5´phosphodiester link (lariat structure in intron) between the adenosine of the branchpoint sequence and the 5´ terminal intronic nucleotide. Second, the free 3´OH group of the 5´ exon performs a nucleophilic attack at the 3´ splice junction, thereby generating a new phosphodiesterbond between the 5´ and 3´ exon resulting in excision of the intronic sequence (Pasman and Garcia-Blanco, 2001).
PLRG-1 and CDC5L have both been shown to be involved in splicing reactions. These nuclear proteins are components of a large complex containing other splicing factors (Ajuh et al., 2000; Burns et al., 1999; Chen et al., 1999; McDonald et al., 1999; Neubauer et al., 1998). This conserved subspliceosomal complex is known as NTC (nineteen complex) in yeast and Prp19/CDC5L complex (Pso4-complex) in mammals (Ajuh et al., 2000; Makarova et al., 2002). Depletion of this complex leads to a block in splicing before the first transesterification step in splicing and lariat formation of the pre-mRNA (Makarova et al., 2002).

Although it was shown that both proteins are essential for splicing per se (Ajuh et al., 2001), mutation of CDC5L in yeast yielded in a G2/M block in part due to incorrect splicing of TUB1 α-tubulin gene (Burns et al., 2002). Mutation of Prp46p (PLRG-1 in mammals) in yeast also results in a G2/M block (Albers et al., 2003). These findings indicate that not only splicing factors are required for correct pre-mRNA splicing, but in addition they play an important role in cell cycle regulation.

Recent findings showed that the SR protein SF2/ASF is a proto-oncogene. Overexpression of SF2/ASF in vitro resulted in immortal rodent fibroblasts. In addition, SF2/ASF is upregulated in many tumors and knockdown of this SR protein inhibits tumor growth (Karni et al., 2007). Furthermore, it was shown that nuclear protein phosphatases, such as PP2Cy, PP1, PP2A or WIP1, are components in spliceosomal assembly and catalysis (Fig 1.1) (Moorhead et al., 2007). These proteins also play functional roles in chromosome condensation (Trinkle-Mulcahy and Lamond, 2006; Vagnarelli et al., 2006), chromatid cohesion (Kitajima et al., 2006), TGFβ signalling (Duan et al., 2006; Knockaert et al., 2006; Lin et al., 2006) or in posttranslational control of p53 (Lu et al., 2005).
In summary, splicing factors assembled in the spliceosome are not only required for correct pre-mRNA splicing. They also play important roles in other pathways, such as cell cycle progression, cytokine signalling or DNA damage response.

Figure 1.1: Schematic representation of splicing reaction

Nuclear protein phosphatases, which are involved in spliceosomal assembly and catalysis are depicted next to arrows. A represents the adenosine in the branchpoint region, YYYY the polypyrrimidine tract, GU the 5’ splice site and AG the 3’ splice site. This scheme was composed based on information from: Hastings et al., 2001; Moorhead et al., 2007
1.3 Role of PLRG-1 in DNA repair

DNA damage is a common cellular event that, if persistent, can lead to mutations, cancer, cell death or even the death of an entire organism. Several cellular responses enable the cell to either eliminate or to cope and survive with the damage or to activate programmed cell death, called apoptosis. These cellular responses include the removal of DNA damage, through repair and restoration of the integrity of the genome, activation of DNA damage checkpoints, leading to cell cycle arrest until damage is restored, transcriptional responses, which change the cellular profile, and apoptosis, when damage is not repairable and cells are severely dysregulated.

The term “DNA damage” comprises genome mutations, as for example in Down syndrome, and chromosomal mutations, such as translocation, deletion, insertion and inversion. Gene mutations are generated spontaneously or by external influences, such as ultraviolet (UV) radiation, inducing reactive oxygen species or leading to DNA base damages, here pyrimidine dimers or photoadducts. Other DNA damages are DNA backbone damages, including abasic sites and DNA single- and double-strand breaks. Abasic sites can develop spontaneously, due to base excision repair or formation of unstable base adducts (Memisoglu and Samson, 1998; Mol et al., 1999; Wilson, 1998). DNA single-strand breaks are caused by DNA damaging agents or as intermediates in nucleotide excision repair (Sancar 1996; Wood, 1997). DNA double-strand breaks are natural intermediates in recombination, but can also be generated by damaging agents, like ionizing radiation (Bonura et al., 1993; Natarajan et al., 1993; Priebe et al., 1994). Other agents, like mytomycin C or cisplatin, lead to interstrand or protein-DNA crosslinks (Jones and Yeung, 1990; Matsumoto et al., 1989; Stevnsner et al., 1993).

The cell relies on various DNA repair mechanisms that are activated in response to DNA damage, including direct repair, base excision repair, nucleotide excision repair, DNA double-strand break repair and repair of interstrand crosslinks.

Direct repair reverses photoadducts resulting from UV-irradiation by photolyases or O\(^6\)-alkyl guanine appearance in DNA by transfer of the alkyl
group from the DNA to a cysteine in O6-alkylguanine-DNA alkyltransferase (Baer and Sancar, 1989; Gerson et al., 1987).

Base excision repair removes a damaged base by generating an apurin or apyrimidine (AP) site and subsequently filling the gap with an undamaged base. Alternatively, a long-patch pathway is used, where a complex consisting of RFC/PCNA-Pol δ/ε enables repair synthesis and nick translation, displacing several nucleotides (Frosina et al., 1996). The flap structure is then cleaved and the long-patch repair is ligated. Nucleotide excision repair is the major pathway for removing bulky adducts and uses a multiprotein complex to resolve DNA damage (Aboussekhra et al., 1995; Evans et al., 1997).

DNA double-strand breaks are repaired either by homologous recombination or nonhomologous end-joining (Takata et al., 1998). The advantage of homologous recombination is the full restoration of the lesion, without losing information, except in cases where the two duplexes are not exactly homologous and gene conversion may take place.

Nonhomologous end-joining is essential for V(D)J recombination and is thought to be the major pathway for DNA double-strand break repair induced by ionizing radiation (DiBiase et al., 2000; Grawunder et al., 1998; Wang et al., 2001). Crosslinks induce DNA double-strand breaks during replication both in vivo and in vitro, presumably due to replication fork collapse and nuclease attack (Bessho, 2003; McHugh et al., 2000; Rothfuss and Grompe, 2004). The major error free pathway involves incision of the crosslinked DNA by the nucleotide excision repair enzymes, followed by gap filling via recombination and involvement of RecA protein (Cole, 1973; Sladek et al., 1989). Another error-prone pathway involved in ICL repair, consists of the NER pathway, subsequently followed by DNA polymerase II-dependent DNA synthesis (Berardini et al., 1999; Jachymczyk et al., 1981).

The mismatch repair factor mutSβ recognizes the ICL by stimulation of PCNA. Subsequently, the WRN protein, RPA and the Pso4-complex are recruited to the point of DNA damage by an unknown mechanism (Zhang et al., 2005). This complex then unwinds the double-stranded DNA, forming single strands near to the interstrand crosslink. The unwound DNA represents a landmark for asymmetrical incisions that release the interstrand crosslink from one strand leading to a gap in the DNA. The heterodimer of the Ercc1 and Xpf
endonucleases produces the incision on both sides of the ICL (Kuraoka et al., 2000). The resulting gap is repaired by either translesion bypass or homologous recombination (Berardini et al., 1997; Berardini et al., 1999; McHugh et al., 2000;) (Fig. 1.2). The gap filling takes place in the following S-phase, where homologous recombination occurs, showing that replication and cell cycle progression are crucial for repairing ICL in mammals (Akkari et al., 2000).

Figure 1.2: Schematic representation of the Pso4-complex in ICL repair
ICL is represented by the connection of the complementary DNA strands. The Pso4 complex consists of tetrameric Pso4, also known as Prp19, CDC5L,PLRG-1 and Spf27. This scheme was composed based on information from: Ohi et al., 2005 and Zhang et al., 2005
However, until now, it is not clear, whether DNA repair proteins participate directly in DNA damage checkpoint responses.

1.4 DNA damage leads to cell cycle arrest

The G$_1$/S, intra-S and G$_2$/M DNA damage checkpoints are responsible for the delay or arrest of cell cycle progression in response to DNA damage. A common feature of these checkpoints is their signal transduction pathway (Fig. 1.3).

![Figure 1.3: Schematic representation of DNA damage checkpoint pathway](image)

Components of human DNA checkpoint protein are depicted here. DNA damage is detected by sensors, which activate with or without the help of mediators, transducers and effectors. The effectors themselves inhibit cell cycle progression until DNA damage is repaired or lead to apoptosis (for p53). Adapted from Sancar et al. 2004

However, the functions of different components of the DNA damage checkpoint pathway are not rigidly defined, as for example the protein ataxia telangiectesia mutated (ATM) can act as a sensor and as a signal transducer (Sancar et al., 2004).

DNA damage is recognized by two groups of proteins: the two phosphoinositide 3-kinase-like kinase (PIKK) family members ATM and ATR and Rad3 related (ATR) and the RFC/PCNA (clamp loader/polymerase clamp)-related Rad17-RFC/9-1-1 complex. ATM and ATR are serine/threonine kinases, whose activation leads to phosphorylation of proteins, such as Chk1, Chk2,
BRCA1 or p53 (Emili, 1998; Gardner et al., 1999; Sanchez et al., 1999; Vialard et al., 1998; Walworth et al., 1993). ATM is activated by DNA double-strand breaks, whereas ATR seems to be more important for DNA damage checkpoint response caused by UV irradiation or stalled replication forks (Guo et al., 2000; Liu et al., 2000; Matsuoka et al., 1998). Mediators like BRCA1 or 53 BP1 link the DNA damage sensors ATM, ATR with the transducers Chk1 and Chk2 (Schultz et al., 2000; Soulier and Lowndes, 1999; Sun et al., 1998; Wang et al., 2002). This signal cascade is required for correct DNA damage checkpoint response leading to a block in cell cycle transition. In mammals, DNA double-strand breaks are sensed by ATM transducing its signal to Chk2, whereas ATR activates Chk1 after UV irradiation (Hirao et al., 2000; Matsuoka et al., 2000; Zhao and Piwnica-Worms, 2001). ATM and ATR phosphorylate p53 at serine 15 leading to its stabilization and activation (Banin et al., 1998; Canman et al., 1998; Lakin et al., 1999). Chk1 and 2 themselves phosphorylate p53 and Cdc25 leading to a G1/S phase block (Lin et al., 1992; Mailand et al., 2000; Melchionna et al., 2000; Sanchez et al., 1997; Shieh et al., 2000; Zhao et al., 2002). Phosphorylation of Cdc25 results in binding to the 14-3-3δ protein excluding Cdc25 from the nucleus and targeting it for degradation by the 26S proteasome (Mailand et al., 2000, Peng et al., 1997). Loss of nuclear Cdc25 results in Cdk2/CyclinE phosphorylation by Wee1 and Myt1 kinases leading to its inactivation (Coulonval et al., 2003; Mailand et al., 2000). This inactive complex is not able to activate Cdc45, thereby inhibiting replication initiation (Costanzo et al., 2003) (Fig. 1.4).
Introduction

The tumour suppressor p53 acts as a major player in a broad range of cellular stress responses. The functional signal transduction circuit of p53 consists of upstream mediators involving DNA damage, hypoxia, nucleotide depletion, aberrant growth signals, and chemotherapeutic drugs (Levine, 1997), whereas the regulatory circuit consists of p53 itself, Mdm2, p14Arf (in mouse p19Arf) and E2F-1, and downstream effectors including genes responsible for cell cycle arrest, such as p21 (el-Diary et al., 1994), inhibition of angiogenesis and metastasis (Kelly-Spratt et al., 2004; Zhang et al., 2000), apoptosis and DNA repair (Ford et al., 1997; Miyashita et al., 1995).

Two regulatory loops are essential for maintaining cellular p53 levels. On the one hand, Mdm2 forms a feedback loop with p53, in which p53 positively regulates Mdm2 by activating its transcription. Mdm2, in turn, negatively regulates p53 by promoting p53 ubiquitination and degradation (Honda et al.,

Figure 1.4: Schematic representation of the G1/S checkpoint
Due to DNA damage, Chk1 and 2 are phosphorylated and activated, leading to Cdc25A and p53 phosphorylation, respectively. On the one hand, Cdc25A phosphorylation leads to its nuclear exclusion and degradation, enabling the phosphorylation and inactivation of CDK2/Cyc E complex by Wee1 and Myt1 kinases. As a result, Cdc45 is not phosphorylated, blocking replication initiation. On the other hand phosphorylation of p53 stabilizes itself and enhances p21 expression, a CDK inhibitor, p21 binds and inhibits CDK4/Cyc D1 complex leading to hypophosphorylation of retinoblastoma protein (Rb, not shown). Rb binds and inhibits E2F, blocking transcription of genes responsible for G1/S-phase progression. Adapted from Sancar et al. 2004.
On the other hand, E2F-1 activates p14\textsuperscript{Arf} transcription, whereas p14\textsuperscript{Arf} facilitates proteolytic degradation of E2F-1 (Mason et al., 2002). These loops are interconnected by p53 and p14\textsuperscript{Arf}. p53 inhibits the transcription of p14\textsuperscript{Arf}, whereas the latter p14\textsuperscript{Arf} interacts with Mdm2, thereby inhibiting ubiquitination and degradation of p53. In turn, p53 inhibits the transcription of p14\textsuperscript{Arf}. (Sancar et al., 2004)

In response to DNA damage, upstream activators of p53, such as ATM, ATR, Chk1 and Chk2 are activated, leading to phosphorylation of p53 and/or Mdm2 (Banin et al., 1998; Shieh et al., 2000). Phosphorylation of these proteins activates p53 through three distinct mechanisms: first by stabilizing p53 by disrupting the binding of Mdm2 to p53; second by enhancing p53 transactivation activity and third by promoting p53 shuttling into the nucleus (Jabbur et al., 2000; Sakaguchi et al., 1997; Unger et al., 1999; Zhang and Xions, 2001). Activated p53 itself activates or represses target genes (e.g. Mdm2) or interacts with other coactivator or transcription factors, such as CBP and Ets1, thereby activating or repressing the transcription of target genes (Alarcon et al., 1999; Lambert et al., 1998; Xu et al., 2002). In addition, p53 promotes apoptosis by activating pro-apoptotic genes, such as Bax, Bad or Apaf-1 (Jiang et al., 2006; Miyishtia et al., 1994; Moroni et al., 2001).

Another target of p53 is the serine/threonine phosphatase WIP1, which dephosphorylates and destabilizes p53 (Lu et al., 2005). WIP1 was found to attenuate UV-induced phosphorylation of p53 at Ser 46 by inactivating p38MAPK and thereby inhibiting apoptosis (Takekawa et al., 2000). Interestingly, over-expression of WIP1 is found in many tumours, including breast cancer (Bernards, 2004).

The intra-S-phase checkpoint is activated by DNA damage or stalled replication machinery occurring in the S-phase leading to a block in DNA replication. This checkpoint requires a large set of checkpoint proteins, such as ATM, the M/R/N complex, MDC1 and BRCA1 (Howlett et al., 2002; Mirzoeva and Petrini, 2001; Scully et al., 1997; Stewart et al., 2003). Due to spontaneous occurrence of DNA double-strand breaks, ATM, ATR and DNA-PK phosphorylate the histone variant H2AX at serine residue 139 (Burma et al., 2001; Park et al., 2003; Ward and Chen, 2001). The phosphorylated H2AX, called γ-H2AX, binds to MDC1, thereby establishing a large zone of modified
chromatin surrounding the DNA double-strand break (Goldberg et al., 2003). The interaction of both proteins enables the recruitment of other factors, such as Nbs1, Rad51 or BRCA1 to the DNA lesion leading to DNA damage repair (Lou et al., 2003; Stewart et al., 2003). These supramolecular structures at DNA double-strand breaks are termed ‘foci’.

Similar to the G$_1$/S checkpoint, an ATM-regulated pathway is responsible for Cdc25A regulation (Xiao et al., 2003). A second pathway depends on the phosphorylation of SMC1 by ATM resulting in DNA synthesis inhibition (Kim et al., 2002; Yazdi et al., 2002).

Activation of the G$_2$/M checkpoint prevents cells progressing into mitosis, a process triggered by p53-mediated regulation of the Cyclin-dependent kinase Cdc2 (Winters et al., 1998). Cdc2 is activated through phosphorylation at threonine 161 by the CDK-activating kinase (CAK) and is bound to Cyclin B (Gu et al., 1992; Larochelle et al., 2007). During the G$_2$ phase, the Cdc2/Cyclin B complex is inactive when Cdc2 is phosphorylated on tyrosine 15 and threonine 14 by the protein kinases Wee1 and Myt1, respectively (Den Haese et al., 1995; Fattaey and Booker, 1997; Mueller et al., 1995). At the transition of G$_2$ into M phase, the phosphatase Cdc25 dephosphorylates Cdc2 (Lammer et al., 1998). In turn, the Cdc2/Cyclin B complex phosphatase further activates Cdc25, initiating a positive feedback loop (Hoffmann et al., 1993; Margolis et al., 2006). Activated Cdc2/Cyclin B complex leads to progression into mitosis (Li et al., 1997). p53 binds and inhibits CAK in vitro, thereby preventing the activation of Cdc2 at threonine 161 (Schneider et al., 1998).

The CDK inhibitor p21 inhibits CDK activity by binding directly to CDK/Cyclin complexes leading to a G$_2$/M arrest (Dulic et al., 1998; Medema et al., 1998). Also, it interferes with the activating phosphorylation of Cdc2 by CAK, thus preventing phosphorylation at threonine 161 (Mandal et al., 1998). Another mechanism involving CDK2-mediated Cdc2 inhibition was shown in *Xenopus*. There, p21 inhibits CDK2 causing loss of Cdc2 activity (Guadagno and Newport, 1996).

Additionally, the p53 target gene *Gadd45* is able to dissociate the Cdc2/Cyclin B1 complex by binding to Cdc2 with its N-terminal part (Zhan et al., 1999).
Another mechanism for the G2/M arrest is the regulation of the subcellular localization of Cdc2. The p53 target gene 14-3-3δ is responsible for nuclear exclusion of Cdc2 (Chan et al., 1999). It binds directly to the Cdc2/Cyclin B1 complex and sequesters it to the cytoplasm.

Furthermore, p53 induces transcription of target genes, such as reprimo (Ohki et al., 2000), B99 (Utrera et al., 1998) and MCG10 (Zhu and Chen 2000). All three proteins contribute to an arrest of cells in G2 phase, but the precise mechanisms of the specific cell cycle arrest are still unknown.

Repression of topoisomerase II is another mechanism for the G2/M arrest by p53 (Sandri et al., 1996; Wang et al., 1997). During the G2/M transition, topoisomerase II is responsible for creating higher order compaction of chromatin and inhibition blocks cells in G2/M progression (Anderson and Roberge, 1996).

When cell cycle progression is impaired due to unreparable DNA damage, the cell induces programmed cell death.

1.5 Regulation of apoptosis in DNA damage and repair

Programmed cell death, called apoptosis, is a crucial and conserved pathway in multicellular organisms (Kerr et al., 1972). The genetically programmed cell death ensures the proper elimination of dysregulated cells and maintains tissue homeostasis. Important roles for apoptosis in many diseases have been revealed in recent years. Lack of apoptosis may result in cancer, while excessive cell death leads to neurodegeneration (Landesman-Bollag et al., 1998; Zuscik et al., 2000). In contrast to necrosis, apoptosis requires energy, concerted action of a cascade of genes and does not lead to inflammation (Fadok et al., 1992; Shiraiishi et al., 2001; Slee et al., 1999). Apoptotic cells shrink and condense, the cytoskeleton collapses, the nuclear envelope dissambles and the DNA is fragmented. Furthermore, apoptotic cells are characterized by cell membrane bledding and phosphatidylserine exposure allowing macrophages to phagocytose them (Fadok et al., 1992).
The tight control of this pathway is essential for every metazoan, because dysregulated apoptosis results in the death of the organism. In mammalian cells, apoptosis is mediated by extrinsic (death-receptor-mediated) and intrinsic (mitochondria-mediated) signaling pathways (Du et al., 2000; Li et al., 2001; Liu et al., 1996; Scaffidi et al., 1998; Susin et al., 1999; Verhagen et al., 2000). However, damage or stress in many organelles such as nucleus or ER (besides mitochondria) may trigger apoptosis (Kaufman et al., 1999; Li et al., 2006; Patil and Walter, 2001; Rich et al., 2000; Zhou et al., 2001). These pathways converge onto a family of proteases, the caspases. Activation of caspase-family proteases is at the core of apoptotic cell death, representing a common point of intersection (Nunez et al., 1998). Common to these proteases is their expression as zymogens that possess a cysteine in their active site, which is responsible for cleaving their substrates after aspartate residues (Alnemri 1997). Caspases that participate in apoptosis can be divided into two major classes, the upstream `initiator` caspases group, consisting of caspases 2, 8, 9, 10 and 12 and the downstream `executor` caspases group including caspases 3, 6 and 7. Caspases collaborate in proteolytic cascades, whereas the activation of the caspases is dependent on the ability of certain procaspases to oligomerize and autoactivate themselves (Srinivasula et al., 1998; Van de Craen et al., 1999).

Procaspsases either assemble at the plasma membrane (caspase 8) or reside in aggregates in the cytoplasm (caspase 9) (Fan et al., 2005). In the first case, binding of either FasL or TNFα to their respective `death` receptors leads to recruitment of pro-caspase 8 (initiator caspase) in the vicinity of the receptor through interaction with the adaptor molecule Fas-associated death domain (FADD). This results in formation of a `death-inducing signal complex` (DISC) and results in the dimerization and autoactivation of procaspase 8 (Kischkel et al., 1995; Medema et al., 1997). In turn, the active caspase 8 leads to activation of executor caspases such as caspase 3 (Woo et al., 1998). The mitochondria-mediated pathway for apoptosis is activated by a myriad stimuli, including growth factor deprivation, oxidant, DNA-damaging agents and others (Aoki et al., 1997; Cook et al., 1999; Lee et al., 2000; Madeo et al., 1999; Maroto and Perez-Polo, 1997; Sanz et al., 2000; Zhan et al., 1994; Zhan et al., 1999).
In the mitochondria-mediated pathway, procaspase 9 (initiator caspase) is recruited to a protein complex called the ‘apoptosome’, which consists of several Apaf-1 molecules. Oligomerization of Apaf-1 is induced by cytochrome c, that is released from the mitochondria (Srinivasula et al., 1998). The following recruitment of procaspase 9 leads to its activation (Srinivasula et al., 1998). This in turn cleaves and activates procaspase 3 (Li et al., 1997). Active caspase 3 will cleave specific vital substrates, such as poly (ADP-ribose) polymerase (PARP), PAK, certain isoforms of PKC and ICAD, resulting in the complete destruction of the cell associated with a typical DNA degradation pattern (‘ladder pattern’) (Frutos et al., 1999; Sakahira et al., 1998 Tewari et al., 1995; Walter et al., 1998)

Mitochondria can also participate in cell death pathways induced via TNF-family ‘death receptors’, through cross-talk mechanisms involving proteins, such as Bid, a pro-apoptotic member of the Bcl-2-family (Grinberg et al., 2005). In addition, caspase 8 cleaves and activates proteins from the Bcl-2 family, such as Bid, which catalyzes the permeabilization of the outer mitochondrial membrane, thus releasing cytochrome c and thereby facilitating the formation of the apoptosome (Kim et al., 2000; Korsmeyer et al., 2000 Li et al., 1998).

However, mitochondrial and death receptor pathway for caspase activation are fully capable of independent operation in most types of cells (Fulda et al., 2001).

1.6 Involvement of the Bcl-2 family in the regulation of apoptosis

Apoptosis and caspase activation can be modulated by members of the Bcl-2 family. This protein family consists of anti- and pro-apoptotic members, which have the ability to prevent or force cells into undergoing apoptosis, through the modulation of mitochondrial release of cytochrome c and other apoptogenic proteins from this organelle (Liu et al., 1996; Scarlett and Murphy, 1997, Susin et al., 1999). It has been shown that the relative amounts of pro- and anti-apoptotic proteins determines the susceptibility of the cell to undergo
Introduction

Apoptosis (Oltvai et al., 1993; Wada et al., 1998). Members of the Bcl-2 family proteins are capable of physically interacting, forming homo- and heterodimers, and function as agonists or antagonists of each other (Gross et al., 1998; Mikhailov et al., 2001; Mikhailov et al., 2003). Pro-apoptotic members of the Bcl-2 family, such as Bax and Bak are capable of forming homo- and heterooligomers, thereby forming a pore, which lead to a limited permeabilization of the outer mitochondrial membrane and release of cytochrome c and apoptogenic factors, such as AlF, thereby leading to initiation of apoptosis (Jurgensmeyer et al., 1998; Kluck et al., 1999; Korsmeyer et al., 2000; Petit et al., 1998; Susin et al., 1998).

There exist at least 20 Bcl-2-related proteins in mammals and all of them possess at least one of four conserved motifs known as Bcl-2 homology domains (BH1 to BH4). Most anti-apoptotic Bcl-2 members contain BH1, BH2 and BH3 domains, whereas Bcl-2 and Bcl-xl possess all four domains (Kelekar and Thompson, 1998). BH1,2 and 3 domains are required for their dimerisation, being essential for pore formation (Mikhailov et al., 2003; Muchmore et al., 1996). The anti-apoptotic members located in the outer mitochondrial membrane inhibit apoptosis by preventing the opening of voltage-dependent anion channels (VDAC), which would lead to an influx of ions, followed by water influx and rupture of the outer mitochondrial membrane, releasing cytochrome c as a result (Narita et al., 1998; Shimizu et al., 1999).

The pro-apoptotic members can further be divided into two subfamilies, members which contain BH1 to BH3 domains, such as Bax, Bak and Bok, and members containing solely the BH3 domain, such as Bik, Hrk, BimL, Noxa, Bad, Puma, Bmf and Bid (Adams and Cory, 1998; Reed et al., 1998). BH3-only proteins are expressed in many different cell types (Hsu et al., 1997; O’Reilly et al., 2000). They are primarily located in the cytoplasm and can relocalize to the outer mitochondrial membrane in response to an apoptotic stimulation, such as DNA damage, to induce cytochrome c release (Gross et al., 1998; Jurgensmeyer et al., 1998).

Pro-apoptotic members, such as Bax and Bak, are able to form homo- and oligomers, as well as heterodimers by binding through their BH 3 domain (Chittenden et al., 1995). This leads to the release of cytochrome c and
activation of caspase 8, initiating the caspase cascade leading to apoptosis (Mikhailov et al., 2003).

The BH3-only protein Bid is cleaved and activated by caspase 8, resulting in a tBid (Li et al., 1998). tBid itself can oligomerize with Bax or Bak forming large pores, thus releasing apoptogenic proteins, such as cytochrome c (Wei et al., 2000).

In response to DNA damage, members of the PIKK family ATM and ATR are activated leading to phosphorylation serine 15 phosphorylation, following by enhanced expression of Bax or by Bax translocation to the mitochondria and reduced Bcl-2 expression (Miyashita et al., 1994; Miyashita and Reed, 1995; Thornborrow et al., 2002). This shifts the ratio between pro- and apoptotic Bcl-2 family members, leading to a pro-apoptotic signal. Furthermore, p53 can activate caspase 8, which results in cleavage of Bid to tBid. tBid translocates to the mitochondria and promotes Bak and Bax assembly generating a transition permeability pore. This leads to apoptosome formation (Haupt et al., 2003), further activation of the caspase cascade and apoptosis (Fig. 1.5).

![Figure 1.5: Apoptosis signalling in response to p53 activation](image)

In response to DNA damage, p53 is activated, promoting the activation of Bax and inhibiting the transcription of Bcl-2. This shifts the ratio between pro- and antiapoptotic Bcl-2 family members leading to a pro-apoptotic signal further promoting apoptosis. IMM and OMM stands for inner and outer mitochondrial membrane.
1.7 Objectives

To elucidate the function of mammalian PLRG-1 *in vivo*, a conventional knockout of PLRG-1 in the mouse was generated using established gene targeting techniques. The targeting strategy resulted in a translational stop after 12 aminoacids ensuring the ablation of the protein. Due to embryonic lethality of the conventional knockout, another conditional gene targeting vector was generated, in which exon 3 was flanked by loxP sites. This construct was introduced into V6.5 ES cells and correctly targeted clones were injected into blastocysts, leading to successful generation of chimeras and germline transmission of the conditional *PLRG-1* allele (*PLRG-1*\(^{\text{flox/+}}\)) onto following generations. Establishing homozygous loxP flanked mouse embryonic fibroblasts (MEF) enabled the functional characterization of PLRG-1 *in vitro* with the use of cell permeable Cre protein. The physiological role of PLRG-1 was defined by crossing mice carrying the conditional PLRG-1 allele with a muscle-specific and a neuron-specific Cre reporter mouse strain to selectively ablate PLRG-1 in these tissues.
2 Materials and Methods

2.1 Chemicals and antibodies

All chemicals used in this work are listed in table 2.1 and were mainly obtained from Sigma (Steinheim, Germany), Merck (Darmstadt, Germany) or Applichem (Darmstadt, Germany), if not otherwise stated.

Restriction enzymes were purchased from the following companies: Invitrogen (Karlsruhe, Germany), MBI Fermentas (St Leon-Rot, Germany), NEB (Schwalbach, Germany), Roche (Mannheim, Germany), and Takara (over Boehringer, Ingelheim, Germany).

Size markers for agarose gel electrophoresis were delivered from MBI Fermentas (Gene Ruler DNA Ladder Mix and λ/HindIII Marker).

Size marker for Pulsed-field gel electrophoresis was delivered from NEB (Yeast chromosome PFG marker).

Size marker for SDS-PAGE gel electrophoresis was purchased from MBI Fermentas (Prestained Protein Ladder Mix).

Table 2.1: Chemicals

<table>
<thead>
<tr>
<th>Chemicals</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agarose</td>
<td>Peqlab, Erlangen, Germany</td>
</tr>
<tr>
<td>Agarose Ultra Pure</td>
<td>Invitrogen, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Agarose Pulse Field Certified</td>
<td>Bio-Rad, München, Germany</td>
</tr>
<tr>
<td>β-Mercaptoethanol</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Boric Acid</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Bovine serum albumin (BSA)</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Calciumchloride (CaCl₂)</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Chloroform</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Desoxy-ribonucleotid-triphosphates</td>
<td>Amersham, Freiburg, Germany</td>
</tr>
<tr>
<td>Dextran sulfate</td>
<td>Amersham, Uppsala, Sweden</td>
</tr>
<tr>
<td>Dimethylformamide (DMF)</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Dimethylsulfoxide (DMSO)</td>
<td>Sigma-Aldrich, Steinheim, Germany</td>
</tr>
<tr>
<td>Disodium hydrogen phosphate</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Dithiothreitol (DTT)</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Ethanol, abs.</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Ethidium bromide</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Ethylenediamine tetraacetate (EDTA)</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Chemicals</td>
<td>Company</td>
</tr>
<tr>
<td>----------------------------------------------------------------</td>
<td>---------------------------------------------</td>
</tr>
<tr>
<td>Fetal calf serum (FCS) for ES cells</td>
<td>PAA, Pasching, Austria</td>
</tr>
<tr>
<td>Fetal calf serum (FCS) for EF cells</td>
<td>Invitrogen, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Gelatin, Type B</td>
<td>Sigma, Steinheim, Germany</td>
</tr>
<tr>
<td>Glacial acetic acid</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Glycerin</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Heps</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Hydrochloric acid (37 %)</td>
<td>KMF Laborchemie, Lohmar, Germany</td>
</tr>
<tr>
<td>Imidazole</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Isopropyl-β-D-Thiogalacto-pyranoside (IPTG)</td>
<td>Biomol, Hamburg, Germany</td>
</tr>
<tr>
<td>Isopropanol (2-Propanol)</td>
<td>Roth, Karlsruhe, Germany</td>
</tr>
<tr>
<td>L (+)-Tartaric acid</td>
<td>Sigma, Steinheim, Germany</td>
</tr>
<tr>
<td>L-Arabinose</td>
<td>Sigma, Steinheim, Germany</td>
</tr>
<tr>
<td>L-Glutamine</td>
<td>Invitrogen, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Luria-Bertani (LB) Agar</td>
<td>Sigma, Steinheim, Germany</td>
</tr>
<tr>
<td>Luria-Bertani (LB) Medium</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Magnesiumchlorid (MgCl2)</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Ni-NTA-agarose</td>
<td>Qiagen, Hilden, Germany</td>
</tr>
<tr>
<td>Nitrogen (liquid) (N₂)</td>
<td>Linde, Pullach, Germany</td>
</tr>
<tr>
<td>N-Lauroylsarcosine</td>
<td>Sigma, Steinheim, Germany</td>
</tr>
<tr>
<td>Non essentiell aminoacids (NEAA)</td>
<td>Invitrogen, Karlsruhe, Germany</td>
</tr>
<tr>
<td>α-P₃²-CTP</td>
<td>Amersham, Freiburg, Germany</td>
</tr>
<tr>
<td>Orange G</td>
<td>Chroma Gesellschaft Schmidt &amp; Co, Stuttgart, Germany</td>
</tr>
<tr>
<td>Phenol/Chloroform/Isoamyalkohol</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Potassium chloride</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Potassium hydroxide</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Proteinase K</td>
<td>Roche, Switzerland</td>
</tr>
<tr>
<td>Roswell Park Memorial Institute medium (RPMI)</td>
<td>PAA, Pasching, Austria</td>
</tr>
<tr>
<td>Salmon sperm DNA</td>
<td>Biomol, Hamburg, Germany</td>
</tr>
<tr>
<td>Sodiumacetate (NaOAc)</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Sodiumchloride</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Sodium-Citrate</td>
<td>Merck, Darmstadt, Germany</td>
</tr>
<tr>
<td>Sodiumdodecylsulfat (SDS)</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Sodiumhydroxide</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
<tr>
<td>Sodiumpyruvate</td>
<td>Invitrogen, Karlsruhe, Germany</td>
</tr>
<tr>
<td>Spermidin</td>
<td>Sigma, Steinheim, Germany</td>
</tr>
<tr>
<td>Trishydroxymethylaminomethan (Tris)</td>
<td>Applichem, Darmstadt, Germany</td>
</tr>
</tbody>
</table>
Materials and Methods

2.2 Molecular biology

Standard methods in molecular biology were performed according to protocols published in Sambrook \textit{et al.} (1989)

2.2.1 Competent \textit{E.coli} and isolation of plasmid DNA

Competent \textit{Escherichia coli} DH5α cells were prepared according to the protocol of Inoue \textit{et al.} (1990) and used for heat shock transformations.

Plasmid DNA was isolated from transformed \textit{E.coli} using an alkaline lysis method (E.Z.N.A.® Plasmid Miniprep Kit 1, Peqlab, Erlangen, Germany) according to the protocol of Zhou \textit{et al.} (1990).

2.2.2 Construction of targeting vectors

All constructs used for vector generation were confirmed by sequencing. Primers used for the generation of targeting vectors are listed in table 2.2.

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence (5´-3´)</th>
<th>Purpose</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>GTA GAC TAA ACG GCG GCG ACA TG</td>
<td>Used for amplification of the short arm of homology for the conventional PLRG-1 targeting vector</td>
</tr>
<tr>
<td>P2</td>
<td>GTG TGT GTA CAG AAT GCA TCT GTA CC</td>
<td>Used for amplification of the short arm of homology for the conventional PLRG-1 targeting vector</td>
</tr>
<tr>
<td>P_long1_5</td>
<td>GGC CGG CCA GGT CTT AAA GGT GCA TAC TCA CAG GAC</td>
<td>Used for amplification of the long arm of homology for the conventional PLRG-1 targeting vector</td>
</tr>
<tr>
<td>Name</td>
<td>Sequence (5´-3´)</td>
<td>Purpose</td>
</tr>
<tr>
<td>------------</td>
<td>--------------------------------------------------------------------------------</td>
<td>-------------------------------------------------------------------------</td>
</tr>
<tr>
<td>P_ long6_3</td>
<td>CTC GAG GCA TCA ATG TCA CCA AAC CTG TAG CAC T</td>
<td>Used for amplification of the long arm of homology for the conventional PLRG-1 targeting vector</td>
</tr>
<tr>
<td>KA5</td>
<td>CGG CCG CGT AGA CTA AAC GGC GGC GAC ATG</td>
<td>Used for amplification of the short arm of homology for the conditional PLRG-1 targeting vector</td>
</tr>
<tr>
<td>KA3</td>
<td>CCG CGG TCA AGG GTC CAA GTG AAT TAA AGA C</td>
<td>Used for amplification of the short arm of homology for the conditional PLRG-1 targeting vector</td>
</tr>
<tr>
<td>flExon3_5</td>
<td>GGC GCG CCG GTC TCA TCC AAA AAG GTT TTG TGT</td>
<td>Used for amplification of the loxP flanked exon 3</td>
</tr>
<tr>
<td>flExon3_3</td>
<td>GGC CGG CCG AAT CAA CTT GAG TTT TCC CTG TAG</td>
<td>Used for amplification of the loxP flanked exon 3</td>
</tr>
<tr>
<td>LA5</td>
<td>CTC GAG CTA GCC TGT GGG GAG ACC ATC T</td>
<td>Used for amplification of the long arm of homology for the conditional PLRG-1 targeting vector</td>
</tr>
<tr>
<td>LA3</td>
<td>GTT TAA ACA AAC ACC CTC TCA CGA GTG GGG</td>
<td>Used for amplification of the long arm of homology for the conditional PLRG-1 targeting vector</td>
</tr>
<tr>
<td>SB5A</td>
<td>CAT TGC TGT ATC GGC GGT ACG TTT</td>
<td>Used for amplification of probe A</td>
</tr>
<tr>
<td>SB3A</td>
<td>CTT GGT GCT CCT TAC TTG GAG GTT</td>
<td>Used for amplification of probe A</td>
</tr>
<tr>
<td>Neo5</td>
<td>TGA ATG AAC TGC AGG ACG AGG CA</td>
<td>Used for amplification of neo probe</td>
</tr>
<tr>
<td>Neo3</td>
<td>GCC GGC AAG CTC TCC AGC AAT AT</td>
<td>Used for amplification of neo probe</td>
</tr>
<tr>
<td>PLRGN5</td>
<td>CAT CAG TAC AGT GCG TGG TGT GA</td>
<td>Used for amplification of PLRG-1 northern probe</td>
</tr>
<tr>
<td>PLRGN3</td>
<td>CTA AAA TCG CTT TCT CTT GAT AAT TTC</td>
<td>Used for amplification of PLRG-1 northern probe</td>
</tr>
</tbody>
</table>
2.2.3 TA-cloning

All PCR products used for gene replacement vectors were first introduced into the TOPO cloning vector (Invitrogen, Germany) using the TA-overhangs generated by PCR following the manufacturer's protocols followed by sequencing.

2.2.4 Generation of gene replacement vectors

All PCR products used for gene replacement vectors were cut out of the TOPO cloning vector containing the short arm of homology, long arm of homology and loxP flanked exon3, respectively, using the appropriate restriction endonucleases. Cloning was performed according to protocols published in Sambrook et al. (1989) and ligation of DNA fragments using the NEB T4-ligase according to the manufacturer’s protocol.

2.2.5 Isolation of genomic DNA

Mouse tail biopsies or cultured cells were incubated overnight at 56°C in lysis buffer (10 mM Tris-HCl [pH 8]; 10 mM EDTA; 150 mM NaCl; 0.2% SDS; 400 mg/ml proteinase K) on a thermomixer. DNA was precipitated by adding an equal volume of isopropanol, mixed and pelleted by centrifugation. The pellet was washed in 70% EtOH, dried, and resuspended in TE-buffer (10 mM Tris-HCl [pH 8]; 1 mM EDTA) plus RNaseI (50 µg/ml). When used for Southern Blotting, DNA was resuspended in TE containing 50 µg/ml RNAse A.

Total DNA from ES cells grown in 96-well tissue culture dishes was extracted according to the protocol of Pasparakis and Kollias (1995).

For the preparation of DNA from mouse tissue, 100 mg tissue was incubated overnight at 56°C in tissue lysis buffer (0.1 M Tris-HCl, [pH 8.5]; 5 mM EDTA; 0.2% SDS; 0.2 M NaCl; 1 g/ml proteinase K) on a thermomixer.
Debris was pelleted and the supernatant was mixed with an equal volume of phenol-chloroform followed by centrifugation. The upper, aqueous phase was transferred to a fresh tube and mixed with an equal volume of chloroform and centrifuged. Finally the upper phase was mixed with an equal volume of isopropanol and centrifuged to precipitate the DNA. The pellet was washed in 70% EtOH, dried and resuspended in TE-buffer.

2.2.6 DNA electrophoresis

DNA fragments were separated by size using electrophoresis in agarose gels (0.7% - 2%; 1xTAE; 0.5 mg/ml ethidiumbromide (Sambrook et al., 1989)). When desired, DNA fragments were excised using a scalpel, and eluted from agarose gel slices using the QIAEX II kit (QIAGEN, Hilden, Germany) following the manufacturer's protocol.

2.2.7 Pulsed-field gel electrophoresis

Pulsed-field gel electrophoresis (PFGE) provides the possibility to separate DNA ranging in size from a few kilobase pairs up to 10 megabase pairs. Because of the large size of these molecules, cell lysis has to occur in agarose embedded plugs. This prevents shearing of the DNA which could lead to diminished quality of the PFGE separations. To generate agarose embedded plugs, the CHEF Genomic DNA Plug Kit from Bio-Rad was used according to manufacturer’s protocol. $10^6$ mouse embryonic fibroblasts were embedded in 100 µl agarose plugs and used for PFGE using the CHEF-DR II system from Bio-Rad. A 1% agarose gel (Pulse Fiel Certified Agarose, Bio-Rad, München, Germany) was run at 6 V/cm$^2$ using pulse times of 70 s for 15 h, followed by 120 s for additional 11 h in 0.5% TBE buffer containing 50 mM Tris-HCl, 50 mM boric acid and 1 mM EDTA. After running, the gel was stained with EtBr to visualize the DNA.


2.2.8 DNA sequencing

DNA was sequenced using the 'Big Dye termination Cycle Sequencing Kit' (Applied Biosystems, Foster City, USA), which is a PCR-based modification of the original Sanger protocol (Sanger et al., 1977). The DNA fragments were analysed automatically using the ABI373A and ABI377 systems (Applied Biosystems, Foster City, USA).

2.2.9 Quantification of DNA

The concentration of nucleic acids was determined by measuring the absorption of the sample at 260 nm and 280 nm in a spectrophotometer. An OD$_{260}$ of 1 corresponds to approximately 50 µg/ml for double stranded DNA. Purity of nucleic acids was estimated by calculating the ratio OD$_{260}$/OD$_{280}$. Pure nucleic acids show a ratio OD$_{260}$/OD$_{280}$ of 2. Protein contaminations decrease this value. Samples with a quotient between 1.8 and 2 are pure enough for DNA quantification.

Residual glass milk from the QIAEX II kit interferes with UV absorption, hence, for estimating the concentration of DNA fragments extracted from agarose gels, a small sample of the DNA was again subjected to electrophoresis, and the concentration was compared to the band intensity of a standard marker.

2.2.10 PCR

The Polymerase Chain reaction (PCR) was used for in vitro amplification of DNA fragments, e.g. for generation of targeting vectors, detecting the presence of targeted alleles or generating fragments for sequencing (Saiki et al., 1985; Saiki et al., 1986). Reactions were performed in Thermocycler iCycler
Genotyping of cells and mice was performed in a total volume of 25 µl containing 250 ng DNA, 25 pmol of each primer, 25 µM dNTP’s, 1.5 mM MgCl₂, 0.75 U *Thermus aquaticus* (Taq) Polymerase (homemade), 10 mM Tris-HCl pH 8.3, 50 mM KCl. PCR started with an initial denaturation at 94°C for 5 min, followed by 30-35 repeating cycles of denaturation at 94°C for 30 s, annealing at 54-57°C for 30 s, elongation at 72°C for 1 min and a final extension step of 10 min at 72°C.

Genotyping of blastocysts, 2-cell stage embryos and fertilized oocytes was performed using a semi-nested PCR (Fig. 2.1). The first PCR generates a large amount of specific DNA fragments using primers for the wildtype (W5.1, W3.2) and the targeted allele (W5.1, 1.2 rev1). These products are used in the second PCR as template. Here, the PCR was performed by using a different internal 5’ primer (W5.2) and the same 3’ primers (W3.2, 1.2 rev1). This technique allows the analysis of a single cell, so the first PCR reaction contained one blastocyste, morula or fertilized oocyte, 25 pmol of each primer, 23.5 µl ddH₂O and 25 µl of a mastermix obtained from Roche. The PCR started with an initial denaturation at 94°C for 2 min, followed by 25 repeating cycles of denaturation at 94°C for 15 s, annealing at 54°C for 30 s, elongation at 72°C for 1 min followed by another round of additional 35 repeating cycles of denaturation at 94°C for 20 s, annealing at 54°C for 30 s, elongation at 72°C for 1.5 min and a final extension step of 10 min at 72°C. 2 µl of the first PCR were used as template for the second PCR, containing 25 pmol of each primer, 22 µl ddH₂O and 25 µl mastermix. This second PCR started with an initial denaturation at 94°C for 2 min, followed by 15 repeating cycles of denaturation at 94°C for 15 s, annealing at 54°C for 30 s, elongation at 72°C for 1 min and additional 25 repeating cycles of denaturation at 94°C for 20 s, annealing at 54°C for 30 s, elongation at 72°C for 1.5 min and a final extension step of 10 min at 72°C.

Amplification of DNA fragments for targeting vectors was performed using the High Fidelity Kit from Roche according to the manufacturer’s guidelines. Primers used for genotyping are listed in table 2.3.
Materials and Methods

Table 2.3: List of primers used for genotyping

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence (5’-3’)</th>
<th>$T_{Ann.}{^\circ C}$</th>
<th>Location</th>
<th>direction</th>
</tr>
</thead>
<tbody>
<tr>
<td>W5.1</td>
<td>GCC AGA CAG</td>
<td>54</td>
<td>Intron 1</td>
<td>sense</td>
</tr>
<tr>
<td></td>
<td>GAG CTT TCT CAT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W5.2</td>
<td>CCT TCT CCA TAT</td>
<td>54</td>
<td>Intron 1</td>
<td>sense</td>
</tr>
<tr>
<td></td>
<td>TTA GCG TGG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>W3.1</td>
<td>CCT CTC TTC ATC</td>
<td>54</td>
<td>Boundary</td>
<td>antisense</td>
</tr>
<tr>
<td></td>
<td>CAA AGG CAC</td>
<td></td>
<td>Exon2/Intron2</td>
<td></td>
</tr>
<tr>
<td>W3.2</td>
<td>TCT CTC TGC ACC</td>
<td>54</td>
<td>Intron 2</td>
<td>antisense</td>
</tr>
<tr>
<td></td>
<td>CTT CTG TTA</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1,2rev1</td>
<td>CCT ACC GGT</td>
<td>55</td>
<td>PGK promoter of</td>
<td>antisense</td>
</tr>
<tr>
<td></td>
<td>GGA TGT GGA</td>
<td></td>
<td>neo’</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ATG TG</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Flp5</td>
<td>GAC AAG CGT</td>
<td>61</td>
<td>N-terminal part</td>
<td>sense</td>
</tr>
<tr>
<td></td>
<td>TAG TAG GCA CAT</td>
<td></td>
<td>of FLP cDNA</td>
<td></td>
</tr>
<tr>
<td>Flp3</td>
<td>GAG AAG AAC</td>
<td>61</td>
<td>C-terminal part</td>
<td>antisense</td>
</tr>
<tr>
<td></td>
<td>GGC ATA GTG</td>
<td></td>
<td>of FLP cDNA</td>
<td></td>
</tr>
<tr>
<td></td>
<td>CGT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>LA2</td>
<td>TGT TAT GTG CAG</td>
<td>55</td>
<td>Intron 1</td>
<td>sense</td>
</tr>
<tr>
<td></td>
<td>TGC CTT TCT</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Seq4</td>
<td>GTC CTC TGT CCA</td>
<td>55</td>
<td>Intron 3</td>
<td>antisense</td>
</tr>
<tr>
<td></td>
<td>AGC ATA TTT G</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MCK5</td>
<td>GTT CTT AAG TCT</td>
<td>60</td>
<td>MCK promoter</td>
<td>sense</td>
</tr>
<tr>
<td></td>
<td>GAA CCC GG</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Figure 2.1: Schematic representation of semi-nested PCR method
Genomic DNA serves as a DNA template for the first PCR. The PCR product of the first PCR serves as a DNA template for the second PCR.
Note: Primer names and sizes of bands are fictitious.
### Materials and Methods

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence(5´-3´)</th>
<th>T_{Ann.} °C</th>
<th>Location</th>
<th>direction</th>
</tr>
</thead>
<tbody>
<tr>
<td>MCK3</td>
<td>GTC TGG ATG ACA TCG TCC AG</td>
<td>60</td>
<td>N-terminal part of MCK</td>
<td>antisense</td>
</tr>
<tr>
<td>Cre_intern_rev</td>
<td>ATG TTT AGC TGG CCC AAA TGT</td>
<td>60</td>
<td>N-terminal part of Cre</td>
<td>antisense</td>
</tr>
<tr>
<td>Syn5</td>
<td>TTC CCG CAG AAC CTG AAG ATG TTC G</td>
<td>59</td>
<td>N-terminal part of SYNCre cDNA</td>
<td>sense</td>
</tr>
<tr>
<td>Syn3</td>
<td>GGG TGT TAT AAG CAA TCC CCA GAA ATG C</td>
<td>59</td>
<td>C-terminal part of SYNCre cDNA</td>
<td>antisense</td>
</tr>
<tr>
<td>Lox5</td>
<td>TGT GAT GGT GGC CGT ATT GAT</td>
<td>54</td>
<td>(Intron3) Between Exon3 and 3´loxP site</td>
<td>sense</td>
</tr>
<tr>
<td>Lox3</td>
<td>CTG TTC CAG CTG TTC TTC ACA</td>
<td>54</td>
<td>Intron3</td>
<td>antisense</td>
</tr>
</tbody>
</table>

Sequences of oligonucleotides are shown in 5´-3´direction. Direction is designated “sense”, if the primer orientation coincides with transcriptional direction, and “anti-sense” vice versa.

### 2.2.11 RT-PCR and quantitative Real-Time PCR

RNA from mouse embryonic fibroblasts was isolated using the RNeasy mini kit (QIAGEN, Hilden, Germany) according to the manufacturer’s protocol. DNase treatment of RNA was performed prior to RT-PCR using the RQ1 Rnase-Free Dnase I endonuclease according to the manufacturer’s guidelines (Promega, Mannheim, Germany). 200 ng total RNA per reaction was used for cDNA synthesis using the One step RT qPCR Master Mix from Eurogentec. 1 µl of cDNA was used for PCR with exon spanning primers (Tab. 2.4)

Quantitative Real-Time PCR was performed using the qPCR Mastermix Plus without UNG kit from Eurogentec with a TaqMan Principles ABI Prism 7700 Sequence Detection System. Relative expression of mRNAs was determined using standard curves based on MEF cDNA. Samples were
adjusted for total RNA content by TBP RNA quantitative PCR. Calculations were performed by a comparative method (2^(-ΔΔCT)). Used samples for quantitative Real-Time PCR are listed in Tab. 2.5.

Table 2.4: List of oligonucleotides used for amplification of cDNA

<table>
<thead>
<tr>
<th>Name</th>
<th>Sequence (5'-3')</th>
<th>T_{Ann.} °C</th>
<th>Location</th>
<th>direction</th>
</tr>
</thead>
<tbody>
<tr>
<td>5CycD1</td>
<td>CTT GAC TGC CGA GAA GTT GTG</td>
<td>54</td>
<td>Exon 2</td>
<td>sense</td>
</tr>
<tr>
<td>3CycD1</td>
<td>AAG TGT TCG ATG AAA TCG TGG</td>
<td>54</td>
<td>Exon 3</td>
<td>antisense</td>
</tr>
<tr>
<td>5CycE1</td>
<td>CTG GGA TGA TAA TTC AGC ATG</td>
<td>54</td>
<td>Exon 5</td>
<td>sense</td>
</tr>
<tr>
<td>3CycE1</td>
<td>AAA GTG CTC ATC TCT CAG GTA</td>
<td>54</td>
<td>Exon 6</td>
<td>antisense</td>
</tr>
<tr>
<td>p53-5RT</td>
<td>AGT CAC AGC ACA TGA CGG AGG</td>
<td>54</td>
<td>Exon 5</td>
<td>sense</td>
</tr>
<tr>
<td>p53-3RT</td>
<td>TGC CTG TCT TCC AGA TAC TCG</td>
<td>54</td>
<td>Exon 6</td>
<td>antisense</td>
</tr>
</tbody>
</table>

Sequences of oligonucleotides are shown in 5'-3' direction. Direction is designated "sense", if the primer orientation coincides with transcriptional direction, and “anti-sense” vice versa.

Table 2.5: List of probes used for quantitative Real-Time PCR

<table>
<thead>
<tr>
<th>Gene name</th>
<th>Abbreviation</th>
<th>Order number</th>
</tr>
</thead>
<tbody>
<tr>
<td>DNA-damage inducible transcript 3</td>
<td>Ddit 3</td>
<td>Mm00492097_m1</td>
</tr>
<tr>
<td>Forkhead box 1</td>
<td>Foxo 1</td>
<td>Mm00490672_m1</td>
</tr>
<tr>
<td>Forkhead box 3a</td>
<td>Foxo 3a</td>
<td>Mm00490673_m1</td>
</tr>
<tr>
<td>Notch1</td>
<td>Notch1</td>
<td>Mm00435245_m1</td>
</tr>
<tr>
<td>Transforming growth factor beta 1</td>
<td>TGF-β1</td>
<td>Mm00441724_m1</td>
</tr>
<tr>
<td>Tubulin alpha 1</td>
<td>Tuba 1</td>
<td>Mm00846967_g1</td>
</tr>
</tbody>
</table>
### 2.2.12 DNA hybridization

10 µg of genomic DNA were digested overnight using 100 U of the appropriate restriction enzyme and separated on a 0.8% agarose gel. DNA was subsequently transferred and immobilized on a nylon membrane (Hybond-N+, Amersham) using an alkaline capillary transfer (Chomczynski and Qasba 1984). To crosslink the DNA with the membrane, membranes were baked at 80°C for 30 min, equilibrated in 2xSSC (Sambrook et al., 1989) and prehybridized at 65°C for 2-4 h in hybridization solution (1M NaCl, 1% SDS, 10% dextran sulfate, 50 mM Tris-HCl pH 7.5, 250 µg/ml sonicated salmon sperm DNA). Probes were labeled with α\(^{32}\)P-dCTP using the Ladderman™ DNA Labeling Kit (TaKaRa, Otsu, Japan) according to the manufacturer’s guidelines. Hybridization of the probe was performed overnight at 65°C. The membranes were washed several times with 2xSSC/0.1% SDS at 65°C until radioactive signals determined with a handheld Geiger counter reached 50 cps. Subsequently, the membrane was sealed in a plastic bag and exposed to an X-ray film (BioMAX MS; Kodak) overnight at -80°C. Films were developed in an automatic developer. Alternatively, membranes were exposed to a phosphoimager screen (Fuji, Fuji, Japan) and analyzed on a Bio-Imaging Analyser (Fuji Bias 1000; Fuji, Japan).

The following probes were used:

1. A **PLRG-1** 5’ probe was PCR amplified from a PLRG-1 BAC using primers SB5A and SB3A resulting in a 498bp fragment.
2. A **Neomycine resistance gene** probe was PCR amplified from pGK12 vector using primers Neo5 and Neo3 resulting in a 510bp fragment.

### 2.2.13 Northern Blot and RNA hybridization

RNA blots from mouse adult tissue (N1334447-BC) and different embryo stages (R1011-SG) were purchased from BioCat. Blots were hybridized with a radiolabeled PLRG-1 probe.

The membrane was prehybridized at 68°C for 2 h in prehybridization solution (Express Hyb, Stratagene, Heidelberg, Germany). A probe was labeled
Materials and Methods

with α^{32}P-dCTP using the Ladderman™ DNA Labeling Kit (TaKaRa, Otsu, Japan) according to the manufacturer’s guidelines. Hybridization of the probe was performed overnight in hybridization solution (Express Hyb, Stratagene, Heidelberg, Germany) containing 100 µg/ml salmon sperm DNA. After hybridization, membranes were washed several times in 2xSSC/0.1% SDS until radioactive signals reached 50 cps. Membranes were sealed in plastic bags and exposed to an X-ray film (BioMAX MS; Kodak) overnight at -80°C.

The following probe was used:

1. A PLRG-1 5’ probe was PCR amplified from bl/6 mouse tail DNA using primer PLRGN5 and PLRGN3 resulting in a fragment of 753bp.

2.3 Cell culture

2.3.1 Primary embryonic fibroblast (EF) culture

Primary EF cells were obtained from mouse embryos at day 13.5 day p.c.

Mice of the desired genotypes were mated and pregnancy was verified by the occurrence of vaginal plugs. 13.5 days after mating, the pregnant mice were sacrificed by cervical dislocation. The mouse was disinfected using Bacillol (Bode Chemie, Hamburg, Germany), the abdomen opened and the uterus containing the embryos dissected. The embryos and placentae were placed in PBS containing 10% Beta-Isodona (Bode Chemie, Hamburg, Germany) and after removal of the placenta embryos were transferred into PBS/7.5% Beta-Isodona. Heart, liver and brain were removed and the residual tissue was placed in PBS, strained through a sterile nylon sieve and washed with EF-medium (Dulbecco’s modified Eagle’s medium (DMEM) containing stable glutamine (Glutamax), 10% FCS, 4500 mg/l glucose, and 1xnon-essential amino acids). The cells were pelleted, resuspended in medium, plated on a 10 cm tissue culture dish (Falcon, Bedford, USA) and grown at 37°C in an atmosphere of 10% CO₂. Primary EF cells were used only up to passage 20.
2.3.2 Embryonic stem (ES) cell culture

For all transfections V6.5 (129Sv x C57BL/6) Embryonic stem cells (Eggan et al., 2002) were used. ES cells were grown at 37°C in an atmosphere of 10% CO₂ in Dulbecco’s modified Eagle’s medium (DMEM) containing 15% fetal calf serum (FCS), 4500mg/l glucose, 1x non-essential amino acids, 2 mM glutamine, 1 mM Na-pyruvat, 0.01 mM β-mercaptoethanol, and 1.3 ml leukemia inhibitory factor. Cells were grown on mitotically inactivated feeder cells, which had been treated with mitomycin C (10 µg/ml for 2 h) and washed extensively with PBS before seeding with ES cells.

ES cell colonies were trypsinized before they reached confluency or after three days. Therefore, cells were washed with PBS and treated with trypsin (0.05 % trypsin, 0.02 % EDTA in PBS; Gibco, Karlsruhe, Germany) for 3 min at 37°C. Trypsin was stopped by adding an equal amount of ES-medium containing FCS to the cells and centrifugation. ES cells were passaged to fresh plates, transfected or frozen (in 90% FCS, 10% DMSO at -80°C, transfer to liquid nitrogen the next day).

For transfection, 1x10⁷ ES cells were mixed with 40 µg DNA in 800 µl transfection buffer (RPMI w/o phenol red, Gibco, Karlsruhe, Germany) in a prechilled electroporation cuvette. For electroporation 500 µF and 240 V at 23°C as standard conditions were used. ES cells were allowed to recover for 5 min on ice prior to seeding on 4x10 cm tissue culture dishes containing an embryonic feeder cell layer.

48 h after transfection, positive selection started using 250 µg/ml G418 (Gibco, Karlsruhe, Germany). Negative selection against HSV-tk containing random integrants started at day five by adding 2x10⁻⁶ M gancyclovir (Cymeven, Syntex, Aachen, Germany) to the medium. On day 9 and 10 after transfection, double resistant colonies were picked from the culture dishes using yellow pipette tips and seeded into EF-containing 96-well tissue culture dishes for recovery and expansion. 3 days after picking the clones, cell samples were frozen, and in parallel expanded for DNA extraction.
2.3.3 HTN-Cre-mediated deletion *in vitro*

Fibroblasts were treated with His-TAT-NLS-Cre (HTNC) to delete loxP-flanked gene segments, which was purified according to Peitz et. al. 2002

3x10^6 cells were plated on a 15 cm cell culture dish. After 4 h, cells were washed twice with PBS and incubated with 5 µM HTN-Cre dissolved in DMEM/PBS. 16 h later, cells were washed with PBS and passaged for the respective experiments.

2.3.4 Cell cycle analysis

HTNC-treated fibroblasts were grown to confluence, washed twice with PBS, serum deprived for 48 h, left untreated or stimulated with 10% FCS for 2, 4, 6, and 8 h, respectively. Cells were trypsinized and counted using an improved Neubauer Haemocytometer. 10^6 cells were lysed in 500 µl 2xSDS sample buffer containing 125 mM Tris-HCl [pH 6.8], 5% SDS, 43.5% glycerol, 100 mM DTT, and 0.02% bromophenol blue and used for immunoblotting.

2.3.5 Cell cycle analysis using fluorescence-activated cell sorter (FACS) analysis

10^6 HTNC-treated fibroblasts were cultured in the absence of serum for 24 h and left untreated or stimulated with 10% FCS for 24 h. Cells were collected by trypsin digestion and fixed in ice-cold 70% EtOH in PBS for at least 2 h. After the removal of ethanol, cells were washed once with PBS, and incubated with 500 µl propidium iodide (PI) staining solution containing 0.1% Triton X-100 (Sigma), 200 µg/ml DNase-free RNase A (Sigma), and 20 µg/ml Propidium Iodide (Sigma) in PBS. 25000 cells were analyzed by FACS (FACSCalibur, Becton-Dickinson Biosciences Immunocytometry Systems) and
the proportion of cells in the G\(_0\)/G\(_1\), G\(_2\)/M, and S phase was assessed using the CellQuest software (Becton Dickinson, Mountain View, USA).

### 2.3.6 \(^3\)H-thymidine incorporation

HTNC-treated fibroblasts were trypsinized and counted using a Neubauer Haemocytometer. \(10^4\) cells were seeded per well (200 µl/well \(\rightarrow\) 5x10\(^4\)/ml) onto a 96-well tissue culture dish and serum deprived overnight. The following day medium was removed and cells were washed once with PBS. Fresh MEF or starving medium containing 5 µCi/ml \(^3\)H-thymidine was added to the. MEFs were incubated with 100 µl of these prepared media for 0, 16 and 24 h. Thereafter, cells were washed with PBS and trypsinized. MEFs were harvested and fixed onto self aligning glass fiber filters (Packard Instrument Company, Downers Grove, USA) using the Packard Harvester Filtermate 196 harvester (Packard Instrument Company, Downers Grove, USA) and airdrying of filters. Incorporated \(^3\)H-thymidine was measured using liquid scintillation counter (Packard Topcount microplate scintillation counter). Counts per minute were used as the readout for proliferation. Calculating the quotient of serum added and serum deprived \(^3\)H-thymidine containing medium resulted in proliferative capacity. For all experiments 48 wells were used for each condition, to receive low standard abbreviations.

### 2.3.7 Analysis of apoptosis

To assess apoptosis, a TUNEL assay (DeadEnd™ Fluorometric TUNEL System, Promega) was used. HTNC-treated fibroblasts were cultivated on glass coverslips in a 6-well plate for 3 days after Cre-treatment. Thereafter, cells were fixed in 4% formaldehyde for 25 min at 4°C and washed twice in PBS. TUNEL assays were performed according to the manufacturer´s guidelines. Percentage
of apoptotic cells was calculated as TUNEL-positive cells per DAPI-stained nuclei.

2.3.8 DNA double-strand breaks after UV-treatment

To determine the occurrence of DNA double-strand breaks, $10^6$ HTNC-treated mouse embryonic fibroblasts were left either untreated or broadband UV irradiated for 2 min using a UV transilluminator (Gel Doc EQ System, München, Germany). Non- and UV-irradiated cells were cultivated for additional 24 h, harvested, agarose embedded (CHEF Genomic DNA Plug Kit, Bio-Rad, München, Germany) and analyzed by PFGE.

2.3.9 Immunofluorescence

HTNC-treated fibroblasts were cultivated on glass coverslips in a 6-well plate for 2 days after Cre-treatment. Thereafter, cells were fixed in 4% paraformaldehyde for 10 min at RT and washed 3 times with PBS. Cells were permealized with 0.5% Triton X-100 and additionally washed another 3 times with PBS. Subsequently, fixed and permealized fibroblasts were blocked with 0.5% BSA in PBS for 45 min at RT. Samples were incubated for 1 hour at RT with an 1:500 γ-H2AX antibody (JBW 301, Millipore, Billerica, USA) dilution in 0.5% BSA/PBS. Following, samples were washed 4 times with PBS, incubated for 45 min at RT with an 1:3000 Alexa-Fluor 555 antibody (Invitrogen, Carlsbad, USA) dilution in 0.5% BSA/PBS and kept in dark. Cells were stained with DAPI in Vectashield to visualize nuclei. Percentage of γ-H2AX positive cells was calculated per DAPI-stained nuclei.
2.3.10 RNA interference (RNAi)

RNAi-mediated knockdown of endogenous PLRG-1 and p53 was performed using Lipofection. PLRG-1 siRNA was purchased from Ambion (16704) and p53 siRNA was purchased from Santa Cruz (sc-44219, sc-29436). si-CONTROL from Dharmacon (D-001210-01) was used as control siRNA. These siRNA duplexes (25 nM) were introduced into MEFs using Lipofectamine 2000 (Invitrogen, Germany) following the manufacturer’s guidelines. 48 h after transfection, cells were harvested and used for TUNEL assay and immunoblotting.

2.4 Biochemistry

2.4.1 Protein extraction from tissue

100-500 mg tissue were dissolved in 1 ml lysis buffer containing 50 mM HEPES [pH 7.4], 1% Triton X-100, 0.1% SDS, 100 mM NaF, 10 mM Na$_2$O$_4$V, 250 mM EDTA, 50 mM NaCl, 10 µg/ml aprotinin, 2 mM benzamidin, 348 µg/ml PMSF, and homogenized using a Ultra Thurrax homogenizer. Protein extracts were centrifuged for 45 min at 4°C to separate supernatants from debris. Protein concentration was measured using a photometer and the Christian-Warburg formula. 10 µg/µl protein stock solution was prepared in 1xSDS sample buffer and heated at 95°C for 5 min. 100µg protein were used for immunoblotting. Protein solutions were always stored at -80°C.

2.4.2 Protein extraction from cells

Collected samples of cells were directly lysed in 2xSDS sample buffer containing 125 mM Tris-HCl [pH 6.8], 5% SDS, 43.5% glycerol, 100 mM DTT,
and 0.02% bromophenol blue and heated at 95°C for 5 min. Lysates of $5 \times 10^4$ cells were loaded and fractionated on 10-15% SDS-PAGE gels. Alternatively, $5 \times 10^5$ cells were lysed in 250 µl 2xSDS sample buffer and heated at 95°C for 5 min. Protein extracts were directly used for SDS-PAGE gel electrophoresis or frozen at -80°C.

### 2.4.3 Nuclear and cytoplasmic protein extraction

Embryonic fibroblasts were washed with PBS. $10^6$ cells were resuspended in 15 µl hypotonic buffer A containing 10 mM HEPES [pH 7.6], 10 mM KCl, 2 mM MgCl$_2$, 0.5 mM DTT, 0.1 mM EDTA, and 1 tablet of Proteinase Inhibitor (Complete mini, Roche, Germany) and incubated for 10 min at 4°C. NP40 were added to a final concentration of 1% and incubated at 4°C for 1 min. Cells were immediately collected by centrifugation at 13000rpm at 4°C for 1 min. The supernatant contained the cytoplasmic fraction. The pellet was washed with buffer A and resuspended in 10 µl high salt buffer B containing 50 mM HEPES [pH 7.8], 50 mM KCl, 300 mM NaCl, 0.5 mM DTT, 0.1 mM EDTA, 10% glycerol, and 1 tablet of Proteinase Inhibitor (Complete mini, Roche, Germany). The pellet was incubated at 4°C on a full speed shaker for 1 h. After incubation, the suspension was centrifuged at 13000 rpm at 4°C for 1 h. The supernatant contained the nuclear fraction.

### 2.4.4 Immunoprecipitation

150 µg nuclear proteins were incubated with 2 µg of anti-WIP1 or anti-insulin receptor (negative control) antibody at 4°C on a rotator for 1 h. Then, 100 µl of Protein A-Sepharose (100 mg/ml, Amersham, Freiburg, Germany) were added and incubated overnight. The suspension was washed 5 times with high salt buffer B, 50 µl 2xSDS loading buffer was added, and samples were
incubated for 5 min at 95°C. The samples were separated on SDS-PAGE gels, and processed for western blot analysis.

### 2.4.5 Western Blot

Proteins were fractionated on 10-15% SDS-PAGE gels (Laemmli, 1970) and semi-dry blotted onto a PVDF-membrane for 30 min to 1 h using a current of 200 mA. Unspecific binding sites were blocked with 1% blocking solution in 1x TBS (20mM Tris [pH 7.6], 0.14 M NaCl) (Amersham, Freiburg, Germany) for 1 h at RT and incubated with appropriate primary antibodies at 4°C overnight (table 2.6). Membranes were washed 4 times for 10 min with TBS-T (1x TBS, 0.1% Tween 20), incubated with respective secondary antibodies, which were coupled to horseradish peroxidase (HRP), at RT for 1 h. Membranes were washed again 4 times for 10 min with TBS-T and signals were detected using the ECL kit (Amersham, Freiburg, Germany).

<table>
<thead>
<tr>
<th>Specificity</th>
<th>Order number</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>AKT</td>
<td>9272</td>
<td>Cell signaling</td>
</tr>
<tr>
<td>β-Actin</td>
<td>1616</td>
<td>Sigma</td>
</tr>
<tr>
<td>Bax</td>
<td>N-20, sc 493</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>Bcl-2</td>
<td>N-19, sc 492</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>CDC5L</td>
<td>612362</td>
<td>BD Transduction Laboratories</td>
</tr>
<tr>
<td>cleaved Caspase 3</td>
<td>9661</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>Cyclin D1</td>
<td>sc 718</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>Cyclin E</td>
<td>C-19, sc 198</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>IR-β</td>
<td>C-19, sc 711</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>Lamin A/C</td>
<td>N-18, sc 6215</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>p21</td>
<td>C-19, sc 397</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>p44/42 MAP kinases</td>
<td>9102</td>
<td>Cell Signaling</td>
</tr>
</tbody>
</table>
### Materials and Methods

<table>
<thead>
<tr>
<th>Specificity</th>
<th>Order number</th>
<th>Company</th>
</tr>
</thead>
<tbody>
<tr>
<td>pp44/42 MAP kinases</td>
<td>9106</td>
<td>Cell Signaling</td>
</tr>
<tr>
<td>p53</td>
<td>FL-393, sc 6243</td>
<td>Santa Cruz</td>
</tr>
<tr>
<td>p-S15-p53</td>
<td>GTX 21431</td>
<td>Gene Tex</td>
</tr>
<tr>
<td>PLRG-1</td>
<td>selfmade</td>
<td>Received from Dr. Paul Ajuh</td>
</tr>
<tr>
<td>WIP1</td>
<td>H-300, sc 20712</td>
<td>Santa Cruz</td>
</tr>
</tbody>
</table>

Secondary antibodies were peroxidase-coupled goat anti-rabbit IgG (whole molecule), anti-goat/sheep IgG (whole molecule) (Sigma), and anti-mouse IgG (whole molecule) (Amersham).

### 2.4.6 Immunohistochemistry

Brains were dissected from 2 to 3 day old mice and snap frozen in tissue-freezing medium (Jung Tissue Freezing Medium; Leica Microsystems, Germany). Sections were performed using a cryostat. Brain slices were either stained with H&E or used for TUNEL assays following manufacturer’s guidelines.

Hearts were dissected from 3 week old mice, frozen in tissue-freezing medium (Jung Tissue Freezing Medium; Leica Microsystems, Germany) and sectioned on a cryostat. Sections were either stained with H&E or processed for TUNEL assays.

### 2.5 Statistical methods

Data was analyzed for statistical significance using a two-tailed unpaired student’s T-Test.
2.6 Animal Care

Care of all animal was within institutional animal care committee guidelines. All animal procedures were conducted in compliance with protocols and approved by local government authorities (Bezirksregierung Köln, Cologne, Germany) and were in accordance with NIH guidelines. Mice were housed in groups of 3 to 5 at 22–24°C using a 12 h light/dark cycle.

2.6.1 Mouse experiments

General handling and breeding of mice was performed according to Hogan (Hogan et al., 1987) and Silver (Silver, 1995).

2.6.2 Mice

C57BL/6 and CB20 mouse strains were ordered from Charles River, Taconic or Jackson Laboratories. Flp deleter mice (Rodriguez et al., 2000) were obtained from our animal facility. PLRG-1^Δ/+ mice were intercrossed to receive homozygous PLRG-1^Δ/Δ mice. MCKCre mice (Brüning et al., 1998) were mated with PLRG-1^floxfloxflox mice, and a breeding colony was maintained by mating PLRG-1^floxfloxflox with PLRG-1^floxfloxMCKCre mice. SynCre mice (Zhu et al., 2001) were mated with PLRG-1^floxfloxflox mice, and a breeding colony was maintained by mating PLRG-1^floxfloxflox with PLRG-1^floxfloxSynCre mice. The SynCre was always transmitted from females, as the transgene has previously been demonstrated to result in germline deletion if transmitted via male germ cells (Rempe et al, 2006).
3 Results

The protein pleiotropic regulator PLRG-1 was identified as a spliceosomal component in vitro, but its functional role in vivo until now has not been examined. To elucidate the function of PLRG-1 in vivo, we generated a gene replacement vector to inactivate the murine PLRG-1 gene. The resulting heterozygous PLRG-1Δ/+ mice exhibited no apparent phenotype, but analysis of the offspring from PLRG-1Δ/+ intercrosses at postnatal day 21 indicated an absence of PLRG-1ΔΔ mice. Detailed inspection of litters at different stages of embryogenesis revealed that homozygous PLRG-1-deficient early embryos were only detectable until embryonic day 1.5.

To determine whether early embryonic lethality caused by the PLRG-1 mutation is due to a general cell cycle defect also manifested in somatic cells, a second gene replacement vector for conditional Cre-loxP-mediated inactivation of PLRG-1 was generated. This allowed a functional characterization of PLRG-1 in vivo, circumventing embryonic lethality and enabling analysis of PLRG-1 deletion in a tissue specific manner. In addition, a line of embryonic fibroblasts, homozygous for the loxP-flanked allele of PLRG-1, was established for in vitro studies. In these cells, deletion of PLRG-1 is achieved through HTN-Cre application.

To obtain mice lacking PLRG-1 specifically in skeletal muscle and heart, PLRG-1floxf/+ mice were crossed with mice expressing a Cre recombinase under control of the muscle specific creatinine kinase (MCK)-promoter (Bruning et al., 1998). Double-heterozygous PLRG-1floxf/+MCKCre mice were crossed with PLRG-1floxf/flox mice to obtain PLRG-1floxf/floxMCKCre offspring, i.e. mice lacking PLRG-1 expression in skeletal muscle and heart (PLRG-1Δmus)

PLRG-1 was also inactivated in the central nervous system (CNS) by intercrossing PLRG-1floxf/flox mice with mice expressing a Cre recombinase under control of the synapsin promoter (Zhu et al., 2001). PLRG-1floxf/flox mice were crossed with double-heterozygous PLRG-1floxf/+SynCre mice to obtain PLRG-1ΔCNS mice with neuron-restricted PLRG-1 deficiency.
Analysis of different mouse lines with distinct tissue specific PLRG-1 ablation and studies with homozygous loxP-flanked mouse embryonic fibroblasts enabled the gain of novel insights into the function of PLRG-1 in vivo and in vitro.

3.1 Murine expression pattern of PLRG-1

In order to determine the expression pattern of the pleiotropic regulator gene 1 (PLRG-1) in C57BL/6 wild type mice, Northern Blot analysis was performed using a PLRG-1 cDNA probe. This analysis revealed the ubiquitous expression of PLRG-1 in all tested organs of adult mice with highest levels in thymus, testis, kidney, brain and spleen (Fig. 3.1A).

In addition, a murine embryo stage Northern blot, containing RNA from embryos of day 4.5 to 18.5, was performed, revealing that PLRG-1 is expressed throughout all phases of mouse embryonic development, showing a peak of steady-state mRNA levels between embryonic days (ED) 10.5 and 14.5 (Fig. 3.1B).

Figure 3.1: Ubiquitous expression of PLRG-1
Northern RNA hybridization analysis of PLRG-1 expression in mice.
(A) Expression analysis of PLRG-1 in tissues from adult mice.
(B) Expression of PLRG-1 in the developing mouse embryo. (ED: embryonic day).
Upper panels show hybridization of the PLRG-1 probe, the lower panels display the corresponding 18S and 28S RNA as loading controls.
3.2 Generation of a conventional PLRG-1 gene replacement vector

The murine gene coding for PLRG-1 comprises 15 exons and spans 17kb of genomic DNA. The C-terminal part of the protein consists of a conserved WD-40 domain of 7 WD-40 repeats. The WD-40 domain is part of many components of multiprotein-complexes and is responsible for protein-protein interactions. The N-terminal part of PLRG-1 is not conserved across different species and contains no known motifs.

To disrupt the PLRG-1 gene using conventional gene targeting techniques, a neomycin resistance cassette was inserted into the second exon of the murine PLRG-1 gene (Fig. 3.2A). This insertion caused a frame shift and a subsequent translational stop of the protein after 12 amino acids. The PLRG-1 targeting vector was generated using the pGK12 vector (Artemis Pharmaceuticals, Köln, Germany), which contains a PGK neomycin resistance cassette, as a positive selection marker, and the Herpes Simplex virus thymidine kinase (TK) gene, as a negative selection marker.

The 1.2 kb short arm of homology comprising exon 1, intron1 and the first 27 bp of exon 2 was amplified from C57BL/6J BAC DNA via PCR. The BAC (RP23-333D8) was constructed in the laboratory of Kazutoyo Osoegawa and Minako Tateno from pooled tissues derived from three female C57BL/6J mice (Osoegawa et al., 2000). The oligonucleotides P1 and P2, used for this PCR, harboured restriction sites allowing a direct cloning into NotI and BamHI sites of the the pGK12 vector after an intermediate subcloning into the TOPO cloning vector (Invitrogen, Karlsruhe, Germany). After a control digest and sequencing, the fragments were cloned into the respective restriction sites of the pGK12 vector.

For verification of correct clones an additional control digest was performed, and homology arms were sequenced. The sequences of used oligonucleotides are depicted in table 2.2.
Prior to electroporation of murine V6.5 ES (129Sv x C57BL/6) cells, 30 µg of vector DNA was linearized with NotI. Successfully electroporated ES cells were double selected with G418 and ganciclovir. After selection, 300 clones were isolated as single, undifferentiated colonies and grown for 3 days. All clones were analysed by Southern Blot analysis or partly used for freezing at -80°C.

The probes used for Southern Blot analysis were PCR amplified from mouse DNA using the primers SB5A and B (probe A), and Neo5 and 3 (probe B). BamHI digestion of the genomic DNA derived from the selected clones and hybridization of probe A was used to determine 5’integration of correctly targeted clones. BglII digest and hybridization of probe B verified single and correct 3’integration of the construct. Out of 300 clones, one homologous recombinant that showed successful insertion of the neo cassette in exon 2 of the PLRG-1 gene could be detected. Hybridization with probe A yielded a recombinant band of 2.6 kb in addition to the 7.8 kb wild type band. Using probe B, a specific band of 9 kb was visible, confirming the homologous recombination (Fig 3.2B).

Homologous recombinant ES cells were injected into C57BL/6 blastocysts, which subsequently were transferred into a pseudo-pregnant foster mouse. Resulting 80-90% chimeric mice were crossed to C57BL/6 mice in order to receive PLRG-1\(^{\Delta+}\) mice.
3.3 Analysis of PLRG-1<sup>Δ+/+</sup> mice

PLRG-1<sup>Δ+/+</sup> mice were viable and did not exhibit any significant differences in size or body weight (Fig 3.3A). The slightly elevated weight of PLRG-1<sup>Δ+/+</sup> females was attributed to the mixed background of this mouse strain. Western Blot analysis of different mouse adult tissues revealed no difference in expression of PLRG-1 in all tested organs (Fig. 3.3B).
Results

Figure 3.3: Analysis of PLRG-1\(\Delta/\Delta\) offspring
(A) Body weight of PLRG-1\(\Delta/\Delta\) (n=14) and wild type males (n=10)
(B) Body weight of PLRG-1\(\Delta/\Delta\) (n=18) and wild type females (n=16)
(C) Expression analysis of PLRG-1 in PLRG-1\(\Delta/\Delta\) and wild type mice. Anti-AKT was used to control for loading. Open squares: wt; filled squares: PLRG-1\(\Delta/\Delta\)

3.4 PLRG-1\(\Delta/\Delta\) mice are embryonic lethal

To generate PLRG-1\(\Delta/\Delta\) mice, PLRG-1\(\Delta/+\) mice were intercrossed. The first analysis of offspring at postnatal day 21 indicated the absence of PLRG-
Results

$1^{\Delta/\Delta}$ mice (Table 3.1). Due to this fact, the genotype of animals was monitored from birth, showing a lack of PLRG-1$^{\Delta/\Delta}$ mice in all inspected litters (Tab.3.1).

In order to define the time point at which PLRG-1$^{\Delta/\Delta}$ mice die, different embryonic stages were investigated, ranging from embryonic day (ED) 0.5 to 18.5. Genotyping of embryos was performed using a semi-nested PCR enabling the amplification of DNA fragments from single cells. A three primer strategy in the first PCR was applied using oligonucleotides in front of exon 2 (W5.1), 3' of exon 2 (W3.2) and 5' of the neomycin resistance cassette (1.2 rev1) (Fig. 3.4A). The PCR product was divided to be used as a template in a second PCR reaction, in order to detect the wild type allele and the deleted PLRG-1 allele. Both PCR reactions depend on the same antisense oligonucleotides, whereas the sense oligonucleotide of the second PCR was designed to anneal 70bp downstream of exon 2 (W5.2) (Fig. 3.4A). This method enabled the identification of different genotypes (Fig. 3.4B).

Detailed inspection of litters at these different stages of embryogenesis revealed that homozygous PLRG-1-deficient embryos were viable until embryonic day 1.5 (Table 3.1 and Fig. 3.4B).

| Table 3.1: Genotype analysis of PLRG-1$^{\Delta/\Delta}$-intercross offspring based on a semi-nested PCR approach |
|----------------------------------|--------|--------|--------|--------|
| PLRG-1$^{\Delta/\Delta}$ x PLRG-1$^{\Delta/\Delta}$ | +/+    | $\Delta/+$ | $\Delta/\Delta$ | Total |
| E 0.5                        | 3      | 11     | 3      | 17    |
| E1.5                        | 6      | 15     | 9      | 30    |
| E2.5                        | 3      | 10     | 0      | 13    |
| E3.5                        | 11     | 15     | 0      | 26    |
| E12.5                       | 3      | 15     | 0      | 18    |
| E18.5                       | 15     | 32     | 0      | 47    |
| P21                         | 33     | 58     | 0      | 91    |

Homozygous PLRG-1-deficient early embryos are only detectable up to embryonic day (ED) 1.5.
Although I could identify PLRG-1-deficient embryos up to ED 1.5, microscopical inspection revealed their substantial degradation (Fig. 3.5). In contrast, wild type embryos exhibited a normal two-cell stage morphogenesis at ED 1.5 (Fig. 3.5).

These results indicate that PLRG-1 plays a crucial role during early embryogenesis at the stage of the first cell division.
3.5 Generation of a conditional PLRG-1 gene replacement vector

As embryonic death of PLRG-1-deficient embryos does not permit any further analysis, I decided to inactivate the PLRG-1 gene conditionally. The targeting vector introduced loxP sites upstream and downstream of exon 3, and deletion of exon 3 by Cre-mediated recombination was predicted to cause a frame-shift mutation resulting in a translational stop after 59 amino acids (Fig. 3.6A).

The pGK12 vector was used and the cloning steps were performed as described for the conventional targeting strategy. To introduce the 2.5 kb short arm of homology consisting of exon 1, intron 1 and the first 27 bp of exon 2 amplified from C57BL/6 BAC DNA via PCR. For this purpose the primers KA5 and KA3 were used containing restriction sites for NotI and SacII, respectively. For amplification of the loxP-flanked exon 3, oligonucleotides flExon3_5 and flExon3_3 harbouring Ascl and Fsel restriction sites were used. The fragment was digested with the respective restriction enzymes and cloned into the pGK12 vector already containing the short arm of homology. The 5 kb long arm of homology consisting of a 5 kb fragment including genomic DNA from exons 4 to 6 was PCR-amplified with the primers LA5 and LA3, containing restriction sites for Xhol and Pmel. The long arm of homology was introduced with the

Figure 3.5: Representative morphology of wild type and PLRG-1-deficient embryos at ED1.5
Wild type embryos show normal two-cell stadium, whereas knockout embryos are degenerated, showing failed division and fragmented nuclei. Shown are representative pictures of 9 embryos of each genotype analyzed.
Results

Respective restriction enzymes into the pGK12 vector already containing the short arm of homology and the loxP-flanked exon 3. The sequences of used oligonucleotides are depicted in table 2.1. All PCR products were subcloned and verified by sequencing and restriction digest analysis. V6.5 (129Sv x C57BL/6) ES cells were electroporated with 30 µg of NotI linearized targeting vector and double selected with G418 and ganciclovir (as described in materials and methods). 450 clones were isolated and analyzed by Southern Blot using the same probes described for the conventional targeting vector (Fig. 3.6A and B). Probe A was used to determine 5’integration of correctly targeted clones after BamHI digestion, resulting in a recombinant band of 4.4 kb besides the 7.8 kb wild type band. BglII digest and use of probe B verified single and 3’integration of the construct through a 5.8 kb band. To confirm the cointegration of the external 3’loxP site, a PCR was performed using oligonucleotides Lox5 and Lox3 (Fig. 3.6C). Four homologous recombinant clones containing the external loxP site could be identified. Injection of one homologous ES cell clone into BL/6 blastocysts yielded in high-grade chimeras transmitting the conditional PLRG-1 allele (PLRG-1^{flox/+}) through germline. Intercrosses of PLRG-1^{flox/+} mice generated PLRG-1^{flox/flox} mice according to the expected Mendelian ratios.
Figure 3.6: Conditional inactivation of the PLRG-1 gene
(A) Schematic representation of the targeting strategy to introduce loxP sites (triangles) into the PLRG-1 locus.
(B) Southern Blot analysis of ES cell clones after electroporation with the targeting construct shown in A. Blots were hybridized with the probes depicted in A. Upper panel: Homologous recombinant (1) displaying a 4.4kb band beside the 7.8kb wild type band using a BamHI digest and probe A specific for PLRG-1. Lower panel: The 5.8 kb band indicates single integration of the targeting vector using BamHI digested DNA and probe B hybridizing to the neomycin resistance gene (1).
(C) PCR analysis with primers flanking the 3'-loxP site confirming co-integration of this loxP site. The 250bp band indicates the wild type (wt) locus, whereas the 320bp band displays the correct integration of the external loxP site (1 and 3).
3.6 Inactivation of PLRG-1 in mouse embryonic fibroblasts blocks cell proliferation

For *in vitro* experiments, mouse embryonic fibroblasts (MEF) from wild type and PLRG-1\(^{\text{floxed/floxed}}\) embryos were generated and treated with recombinant, cell permeable Cre protein (HTNC) (Peitz et al., 2002). Cre-treatment resulted in efficient removal of exon 3 from the PLRG-1\(^{\text{floxed/floxed}}\) locus as verified by PCR using oligonucleotides LA2 and Seq4, yielding a 1.7 kb band for wild type and a 1 kb band for PLRG-1\(^{\text{floxed/floxed}}\) MEF treated with HTNC (Fig. 3.7A and B). MEFs carrying the resulting *PLRG-1* mutant locus lacked detectable PLRG-1 protein expression as verified by Western Blot analysis (Fig. 3.7C).

**Figure 3.7: Verification of PLRG-1 deletion in MEFs upon HTNC treatment**

(A) Schematic representation of PCR primer locations
(B) PCR analysis of wild-type (lanes 1 and 2) and PLRG-1\(^{\text{floxed/floxed}}\) MEF (lane 3, ∆) after treatment with cell permeable Cre-protein using primers LA2 and Seq 4.
(C) Western Blot analysis of wild type (lane 1) and PLRG-1\(^{\text{floxed/floxed}}\) MEFs (lane 2) after HTNC treatment.
Results

As the conventional PLRG-1 knockout in mice resulted in a defect in cell division during embryogenesis, the growth rate of wild type and PLRG-1\textsuperscript{flox/flox} MEFs was determined in the absence or presence of HTNC treatment. Cells were incubated overnight in serum free DMEM with or without HTNC, thereafter re-exposed to medium supplemented with fetal calf serum and were counted every day using a Neubauer Hemocytometer.

Cre-treatment of PLRG-1\textsuperscript{flox/flox} MEFs resulted in an immediate growth arrest of these cells, while having no effect on wild type MEF proliferation compared to untreated wild type and PLRG-1\textsuperscript{flox/flox} MEFs (Fig. 3.8A). Also, PLRG-1-deficiency in MEFs resulted in a larger cell size, potentially due to a block in G\textsubscript{0}/G\textsubscript{1}- or in G\textsubscript{2}/M-phase (Fig. 3.8B).

This phenotype is similar to the phenotype observed in conventional PLRG-1 knockout mice, in which the PLRG-1 mutation resulted in a failure to execute the first cell division during embryogenesis, emphasizing the assumption that PLRG-1 is essential for cell proliferation.
Results

3.7 PLRG-1 deficiency prevents S-phase entry

To define the precise role of PLRG-1 during cell proliferation, analysis of serum stimulated cell cycle progression in wild type and PLRG-1-deficient MEFs by fluorescence activated cell sorting (FACS) was performed. Using propidiumiodide (PI) as an intercalating dye for DNA, it is possible to distinguish between G₀/G₁-, S- and G₂/M-phase. The first peak in a FACS histogram...
represents the G₀/G₁-phase, in which cells contain the normal 2n DNA content. The following S-Phase is relatively short with a duration of approximately 2 to 4 hours. It contains an intermediate DNA content and is depicted in a histogram as the phase between the two peaks. The second peak displays the G₂/M-phase, which is characterized by the double 4n DNA content after S-phase and is the last phase before entering mitosis and cytokinesis. Here again cells grow until they receive the signal to progress into mitosis. To perform this experiment, cells have to be synchronized by serum depletion for 24 – 48 h resulting in resting cells in G₀/G₁ phase. After addition of serum, cells will progress simultaneously into cell cycle allowing the distinction between the different cell cycle phases.

While serum stimulation resulted in G₁- to S-phase progression in wild type cells in both absence and presence of recombinant Cre protein, the S-phase entry was blocked in PLRG-1^{floxed/ox} MEF after HTNC treatment (Fig. 3.9).

<table>
<thead>
<tr>
<th></th>
<th>WT -FCS</th>
<th>WT +FCS</th>
<th>KO-FCS</th>
<th>KO+FCS</th>
</tr>
</thead>
<tbody>
<tr>
<td>G₀/G₁-Phase</td>
<td>62.4%</td>
<td>49.8%</td>
<td>51.4%</td>
<td>51.1%</td>
</tr>
<tr>
<td>S-Phase</td>
<td>2.3%</td>
<td>5%</td>
<td>2.3%</td>
<td>3.2%</td>
</tr>
<tr>
<td>G₂/M-Phase</td>
<td>35.3%</td>
<td>45.2%</td>
<td>46.3%</td>
<td>45.7%</td>
</tr>
</tbody>
</table>

Figure 3.9: FACS analysis of serum (FCS)-stimulated cell cycle progression in control and PLRG-1-deficient MEFs

Different cell cycle phases of wild-type and PLRG-1-deficient MEFs before serum stimulation (-FCS: left) and 24 h after serum stimulation (+FCS: right). Distribution of cell cycle phases obtained from three independent experiments are summarized in the table.
Results

To confirm the observed block in cell cycle as revealed by FACS analysis, a $^3$H-thymidine incorporation assay was performed. This method determines the ability to replicate DNA by measuring the incorporation of $^3$H-thymidine into newly synthesized DNA. Therefore, cells were again synchronized by serum deprivation to start in the G₀/G₁-phase and were then stimulated with 10% FCS to initiate cell cycle progression. The $^3$H-thymidine content of wild type and PLRG-1$^{flox/flox}$ MEFs treated with HTNC protein was measured at 0, 16 and 24 h after FCS stimulation. PLRG-1-deficient MEFs did not incorporate $^3$H-thymidine at any time point, which confirmed the disability to progress into the S-phase (Fig. 3.10), demonstrating that PLRG-1 is required for serum-stimulated G₁/S-phase transition in murine cells.

![Figure 3.10: $^3$H-thymidine incorporation of wild type and PLRG-1-deficient MEFs](image)

$^3$H-thymidine incorporation was measured after 0, 16, and 24 h of serum stimulation in wild-type (open bars) and PLRG-1-deficient (closed bars) MEFs. Values represent mean ± SEM values from three independent experiments (*p* < 0.05).

3.8 PLRG-1 deficiency increases p53 expression and induces apoptosis

To investigate the molecular mechanism by which PLRG-1 ablation prevents cells from entering the S-phase, the early regulatory steps of G₁/S transition were examined using biochemical approaches. Wild type and PLRG-1$^{flox/flox}$ MEFs were treated with cell permeant Cre-protein to delete PLRG-1, serum deprived for 48 h to synchronize MEFs in G₀/G₁-phase and subsequently stimulated with 10% FCS to progress into cell cycle. Cells were harvested,
lysed and cellular proteins were separated by SDS-PAGE, transferred onto PVDF membranes to determine expression and phosphorylation of proteins responsible for G1/S-phase progression, such as Erk1 and Erk2 MAP kinases, which are key mediators of proliferative signalling by Western Blot analysis. In addition, proteins, which are expressed as a result of Erk1 or Erk2 activation, such as Cyclin D1 and Cyclin E, were also analyzed.

During G1- to S-phase progression, Cyclin D1 binds CDK4 and allows for the hyperphosphorylation of Retinoblastoma (Rb) protein, leading to a release of the transcription factor E2F. E2F is responsible for transcription of proteins involved in DNA replication and cell cycle progression, such as MCM proteins and Cyclin E. Cyclin E, in turn, activates more CyclinD1/CDK4 complexes, thereby promoting the G1-S-phase progression.

Expression and activation status of other proteins involved in a G1/S-phase block, namely p53, stabilized S15-phosphorylated p53 and CDK inhibitor p21, were also determined.

Examination of the regulatory steps of G1/S transition revealed an unaltered biphasic activation of MAP kinases Erk1 and Erk2 in both wild type and PLRG-1-deficient MEFs upon serum stimulation (Fig. 3.11) (Balmanno and Cook, 1999). In contrast, serum stimulated Cyclin D1 expression was dramatically reduced in PLRG-1-deficient MEFs compared to wild type cells (Fig. 3.11). The mutant cells also displayed significantly lower Cyclin E expression (Fig. 3.11). Concomitantly, expression of p53, and also, during later time points of serum stimulation, of CDK inhibitor p21 were increased in the absence of PLRG-1 (Fig. 3.11).

The activity of p53 is tightly controlled via posttranslational modification, in particular through stabilization by phosphorylation (Nakagawa et al., 1999; She et al., 2000; Vega et al., 2004). Therefore, the phosphorylation state of p53 was analyzed by immunoblotting using an antibody recognizing phosphorylated p53 at serine 15. During the course of serum stimulation, remarkably higher levels of p53 phosphorylation at serine 15 were observed in PLRG-1-deficient cells compared to wild type cells (Fig. 3.11). Taken together, the elevated levels of phosphorylated p53 protein correlate with the block of S-phase transition and the increase of CDK-inhibitor p21 levels in MEF cells lacking PLRG-1.
Since continuously elevated p53 levels are known to induce apoptosis (M. Schuler, 1997), I directly addressed whether apoptosis is increased in PLRG-1-deficient MEFs. Therefore, TUNEL assays were performed, which revealed a dramatic induction of apoptosis in PLRG-1-deficient MEFs compared to wild type controls (Fig. 3.12). PLRG-1-deficient MEFs exhibited approximately 7%, whereas wild type cells displayed 0.5% of apoptotic cells (Fig. 3.12).

To further characterize p53-induced apoptosis, expression of p53 targets and downstream effectors of apoptosis was determined. Caspase 3, an aspartate-specific cysteine protease, is a key executor of apoptosis and is typically activated by proteolytic processing. It triggers apoptosis by cleavage of different cytosolic and nuclear substrates, such as poly (ADP-ribose) polymerase (PARP) and ICAD. Consistent with the detection of enhanced apoptosis, cleavage of caspase 3 was also dramatically increased, as assessed by Western Blot (Fig. 3.12). This was paralleled by increased levels of the pro-apoptotic Bax protein, its gene being a well-characterized target of p53, along with a slight decrease in the level of anti-apoptotic Bcl-2-protein in PLRG-1-deficient MEFs (Fig. 3.12).

In summary, these experiments indicate that PLRG-1 deficiency blocks G_1/S-phase transition and stimulates apoptosis, possibly as a consequence of increased p53 phosphorylation and stabilization.
3.9 No evidence for altered splicing in PLRG1-deficient MEFs

As PLRG-1 has been initially identified as a component of the spliceosome and as peptides interfering with the PLRG-1/CDC5L interaction inhibit pre-mRNA-splicing in vitro, the question was addressed, whether PLRG-1 deletion results in pre-mRNA accumulation and a reduction of mRNA. Therefore, RNA from untreated and HTNC-treated PLRG-1$^{\text{floxed/floxed}}$ MEFs was isolated 48 h after Cre-treatment. RNA was Dnasel digested and used for RT PCR. Following, PCR using exon spanning primers for Cyclin D1 (5CycD1, 3CycD1), Cyclin E1 (5CycE1, 3 CycE1) and p53 (p53-5RT, p53-3RT) were performed, to investigate splicing defects of these genes. DNA was used as positive control for detectability of unspliced products, i.e. pre-mRNA. PLRG-1-deficient MEFs did not show aberrant splicing of these genes displaying correct spliced products as observed in untreated PLRG-1$^{\text{floxed/floxed}}$ MEFs (Fig 3.13 A and
B). Thereby, reduced Cyclin D1 and E1 expression in PLRG1-deficient MEFs shown in serum stimulated cell cycle progression was not due to aberrant splicing of these genes.

For further validation quantitative Real-time PCR was performed using probes for genes involved in ER stress (Ddit 3), transcriptional and cell cycle regulation (Foxo 1, Foxo 3a), Notch signalling (Notch 1), inflammation (TGF-β1) and cytoskeletal formation (Tuba 1). No difference in expression of these genes was observed, except for α-tubulin, which was 1.5 fold increased in PLRG-1-deficient MEFs (Fig. 3.13 C). This was consistent with the findings in PLRG-1-deficient MEFs, which display an increased cell size.

Figure 3.13: Splicing in PLRG-1-deficient MEFs is unaltered
(A) PCR analysis of untreated (C) and HTNC treated PLRG-1\(^{\text{lox/lox}}\) MEF (KO) using primers lox3 and lox5 for the loxP flanked allele and LA2 and Seq 4 for the deleted allele
(B) PCR analysis based on cDNA and exon spanning primers. Control and KO samples show no aberrant splicing. DNA represents the unspliced variant of Cylin D1, Cyclin E1 and p53
(C) Expression analysis of PLRG-1\(^{\text{lox/lox}}\) (open bars) and PLRG-1-deficient (closed bars) MEFs of Ddit 3, Foxo 1, Foxo 3a, Notch 1, TGF-β1 and Tuba 1 using quantitative Real-time PCR. Samples were adjusted for total RNA content by TBP RNA quantitative PCR

Taken together, these results indicate, that PLRG1-deficient MEFs did not suffer from general alteration in pre-mRNA-splicing, as proposed for yeast or mammals using an adeno-pre-mRNA vector for splicing assays.
3.10 PLRG-1-deficient MEFs exhibit no spontaneously detectable DNA double-strand breaks

Since p53 phosphorylation and accumulation represents a response to DNA damage and as it was recently demonstrated, that PLRG-1 is a component of the Pso4-complex, which uncouples DNA interstrand crosslinks, thus ensuring genomic integrity, I next directly addressed whether PLRG-1 deficiency results in spontaneously detectable DNA double-strand breaks.

Therefore, PLRG-1\(^{\text{flox/flox}}\) MEFs left untreated or treated with cell permeable Cre. 48 h after HTNC treatment, MEFs left either unirradiated or were UV irradiated for 2 min to induce genomic instability, namely DNA double-strand breaks. 24 h after UV-irradiation, cells were harvested, agarose embedded, lysed and used for pulse-field gel electrophoresis. Fragmented DNA was released into the gel and visualized using EtBr staining, whereas highmolecular and unfragmented DNA remained in the agarose plugs. Untreated and HTNC-treated MEFs showed no difference in DNA release into the gel, indicating that PLRG-1 deficiency per se did not cause DNA double-strand breaks, whereas UV-irradiated cells displayed DNA fragmentation, resulting in DNA release into the pulse-field gel to similar extend in PLRG-1\(^{\text{flox/flox}}\) and deficient MEFs (Fig. 3.14).

![Figure 3.14: Pulse-field gel electrophoresis of PLRG-1\(^{\text{flox/flox}}\) (control) and PLRG-1-deficient MEFs (KO)](image)

PLRG-1\(^{\text{flox/flox}}\) MEFs left untreated or treated with HTNC. As control for DNA fragmentation, cells were UV treated. The gel shows two control versus two KO samples.
In summary, these experiments indicate that PLRG-1 deficiency does not enhance genomic instability, by promoting occurrence of spontaneous DNA double-strand breaks.

3.11 PLRG-1 deficiency results in enhanced γ-H2AX phosphorylation

As a consequence of stalled replication forks or DNA double-strand breaks spontaneously occurring during DNA replication, the phosphorylation of γ-H2AX was investigated using immunofluorescence. γ-H2AX represents a variant of histone proteins, which are phosphorylated by members of the PIKK-family, such as ATM and ATR, thereby recruited to stalled replication forks or DNA lesions.

Therefore PLRG-1-deficient MEFs were investigated in terms of γ-H2AX phosphorylation. PLRG-1\(^{\text{flox/flox}}\) MEFs left untreated or treated with cell permeant Cre protein. 48 h after HTNC treatment, cells were fixed and stained with phospho-S139-γ-H2AX antibody. PLRG-1-deficient MEFs showed enhanced γ-H2AX phosphorylation compared to untreated PLRG-1\(^{\text{flox/flox}}\) MEFs displaying an increase in γ-H2AX foci (Fig. 3.15A). About 90% of PLRG-1-deficient MEFs were γ-H2AX positive compared to 10% of untreated MEFs (Fig. 3.15B) These data indicate that PLRG-1 deficiency results in increment of γ-H2AX foci as a result of stalled replication forks, rather than DNA double-strand breaks as shown in figure 3.14 using PFGE.

![Figure 3.15: Analysis of γ-H2AX phosphorylation in untreated and HTNC-treated PLRG-1\(^{\text{flox/flox}}\) MEFs](image_url)

(A) Photomicrograph of phospho-S139-γ-H2AX-stained PLRG-1\(^{\text{flox/flox}}\) (Control) and PLRG-1-deficient MEFs (KO). Representative S139-γ-H2AX-positive cells are marked by white arrows. (B) Percentage of γ-H2AX positive cells in control and PLRG-1-deficient MEFs. Values represent mean ± SEM from three independent experiments (***p < 0.001)
3.12 Conditional inactivation of PLRG-1 in heart and skeletal muscle

To examine developmental regulatory effects of PLRG-1 in vivo, mice with conditional tissue-specific inactivation of the PLRG-1 gene were generated. To obtain mice lacking PLRG-1 specifically in skeletal muscle and heart, PLRG-1 flox/+ mice were crossed with mice expressing the Cre recombinase under the control of the muscle-specific creatinine kinase (MCK) promoter (Brüning et al., 1998). Double-heterozygous PLRG-1 flox/+MCKCre mice were crossed with PLRG-1 flox/flox mice to obtain PLRG-1 flox/floxMCKCre offspring lacking PLRG-1 expression in skeletal muscle and heart (PLRG-1 mus). As in the case of conventional PLRG-1-deficient knockout mice, the analysis of offspring from these breedings at postnatal day 28 revealed the absence of PLRG-1 mus mice, indicating that PLRG-1 deficiency also in skeletal muscle and heart results in early lethality (Table 3.2).

However, in contrast to the conventional knockout mice, PLRG-1 mus mice were detected at the expected Mendelian frequency at birth (Table 3.2) leading to the assumption that during early lifespan a deficit in heart and skeletal muscle occurs due to PLRG-1 deficiency. To confirm heart- and muscle-specific recombination of the PLRG-1 gene in PLRG-1 mus mice, genomic DNA was extracted from individual tissues of PLRG-1 flox/flox and PLRG-1 mus mice at postnatal day 5 and subjected to PCR analysis using the oligonucleotides LA2 and Seq4 as shown in figure 3.7. Surprisingly, only in heart successful recombination could be detected (Figure 3.16). Presumably, expression and activity of MCKCre in skeletal muscle is initiated during later stages of murine development. Deletion efficiency in heart was not 100%, as can be concluded
from the appearance of a PCR product for the floxed allele besides the band for the deleted allele. It is possible that full Cre expression and activity in heart cannot be reached before failure of the organ.

Close postnatal monitoring of the litters revealed that, while 80% of control mice survived the first 28 days of life, the survival rate of PLRG-1\textsuperscript{Δ\emus} mice was dramatically reduced to 5% during the same period (Fig. 3.17). The premature death of control animals displays normal values for animals kept under standard animal care in the animal facility.
3.13 Conditional inactivation of PLRG-1 in heart results in dilated cardiomyopathy due to increased cardiomyocyte apoptosis

Because Cre-mediated recombination was only detectable in heart, heart function in mice surviving up to postnatal days 24 to 26 was investigated. Opening of the thorax revealed an increase in heart size in PLRG-1Δmus mice (Fig. 3.18A) Consistent with this observation, quantitative assessment of heart mass revealed an increase in heart weight of PLRG-1Δmus mutant compared to control mice (PLRG-1flox/flox) (Fig. 3.18B)

![Image](A) Control KO

![Image](B) Ratio heart/body-weight

**Figure 3.18: Heart-phenotype of PLRG-1Δmus mice**
(A) Autopsy of postnatal day 24 control (PLRG-1flox/flox) and PLRG-1Δmus (KO) mice. Note the enlarged heart for PLRG-1Δmus compared to control.
(B) Relative heart/body weight ratio in control and PLRG-1Δmus mice. Data represent the mean ± SEM of seven control and six PLRG-1Δmus mice (**p < 0.001).

Haematoxylin / Eosin staining and histological analysis of hearts at postnatal day 24 demonstrated severe thinning of both ventricle walls and
massive dilatation of both left and right ventricle in hearts derived from PLRG-1^Δmus, reflecting the pathology of severe dilated cardiomyopathy (Fig. 3.19).

Taking into account the results obtained from the analysis of PLRG-1-deficient MEFs, the question arose, whether the heart dilation was due to increased apoptosis of cardiomyocytes. In fact, TUNEL staining of explanted heart tissue revealed an increase in apoptotic cardiomyocytes in the PLRG-1^Δmus mice compared to control mice (Fig. 3.19).

Western blot analysis of protein extracts from hearts of control and PLRG-1^Δmus mice showed increased Bax and decreased Bcl-2 expression (Fig. 3.20). Consistent with the previous findings in PLRG-1-deficient MEFs, hearts of PLRG-1^Δmus mice also showed higher levels of phosphorylated p53 (Fig. 3.20). Taken together, these results establish the underlying molecular basis of PLRG-1^Δmus pathology, which is characterized by dilated cardiomyopathy due to increased cardiomyocyte apoptosis in the presence of enhanced p53 phosphorylation along with increased Bax and decreased Bcl-2 expression. The data also demonstrate that the PLRG-1-dependent pathway regulating

---

Figure 3.19: Histological analysis of control- and PLRG-1^Δmus-hearts at the age of 24 days
The upper panel shows H&E stained control and PLRG-1^Δmus hearts. The lower panel shows TUNEL stained heart sections, revealing increased cardiomyocyte apoptosis in PLRG-1^Δmus hearts.
apoptosis, as determined for PLRG-1-deficient MEFs, is also functional in tissues of postnatal mice.

Figure 3.20: Western blot analysis of control (C) and PLRG-1<sup>ΔCNS</sup>-(KO) hearts
Expression of total cellular protein extracts of p53, S15-phospho-p53 (pp53), Bcl-2 and Bax was analyzed by western blotting. Anti-AKT was used to control for equal loading.

### 3.14 Conditional inactivation of PLRG-1 in the central nervous system of mice results in early postnatal lethality

To investigate whether the observed phenotype of PLRG-1 deficiency represents a more general phenomenon, PLRG-1 was also inactivated in another predicted non-mitotic organ, i.e. the post-mitotic neurons in the central nervous system (CNS), by intercrossing PLRG-1<sup>ΔCNS</sup> mice with mice expressing the Cre recombinase under control of the Synapsin promoter (Zhu et al., 2001). The Cre transgene was always transferred maternally due to an undesired germline activity in males (Rempe et al., 2006). PLRG-1<sup>ΔCNS</sup> mice were crossed with PLRG-1<sup>ΔCNS</sup> mice with neuron-restricted PLRG-1 deficiency. These mice also revealed early lethality as no PLRG-1<sup>ΔCNS</sup> mice reached the age of weaning (Table 3.3).

#### Table 3.3: Genotype analysis of mice obtained from breedings of PLRG-1<sup>ΔCNS</sup> mice with PLRG-1<sup>ΔCNS</sup> SynCre mice

<table>
<thead>
<tr>
<th></th>
<th>PLRG-1&lt;sup&gt;ΔCNS&lt;/sup&gt;</th>
<th>PLRG-1&lt;sup&gt;ΔCNS&lt;/sup&gt; SynCre</th>
</tr>
</thead>
<tbody>
<tr>
<td>P1</td>
<td>11</td>
<td>13</td>
</tr>
<tr>
<td>P21</td>
<td>8</td>
<td>8</td>
</tr>
</tbody>
</table>
Monitoring of the litters directly after birth showed an even more dramatic phenotype of PLRG-1\(^{\Delta \text{CNS}}\) mice than PLRG-1\(^{\Delta \text{mus}}\) mice. PLRG-1\(^{\Delta \text{CNS}}\) mice had survival rates of only 25% at postnatal day 3, while control mice showed an 88% survival rate, representing normal surviving variations of mouse populations in standard animal facilities. On postnatal day 9 no surviving PLRG-1\(^{\Delta \text{CNS}}\) mice were observed, indicating again the important role PLRG-1 plays in the developing mouse (Fig. 3.21).

PCR analysis of genomic DNA derived from 3 day old control and PLRG-1\(^{\Delta \text{CNS}}\) mice at postnatal day 3 using oligonucleotides LA2 and Seq4, confirmed CNS-restricted recombination of the PLRG-1 gene in PLRG-1\(^{\Delta \text{CNS}}\) mice (Fig. 3.22). Again, deletion was not complete, since full Cre expression and activity would require longer survival.

![Figure 3.21: Survival rate of control and PLRG-1\(^{\Delta \text{CNS}}\) mice](image)

**Figure 3.21: Survival rate of control and PLRG-1\(^{\Delta \text{CNS}}\) mice**

Survival rate of control (n = 25 (PLRG-1\(^{\text{flox/flox}}\), PLRG-1\(^{\text{flox/+}}\) and wild type)) and PLRG-1\(^{\Delta \text{CNS}}\) (n = 12) mice at days 1, 3, and 9.

![Figure 3.22: Analysis of neuron-restricted recombination of the PLRG-1\(^{\text{flox/flox}}\) allele](image)

**Figure 3.22: Analysis of neuron-restricted recombination of the PLRG-1\(^{\text{flox/flox}}\) allele**

The panel shows specific deletion of PLRG-1 in the brain of PLRG-1\(^{\Delta \text{CNS}}\) mice (KO). Using a primer pair flanking exon 3, the appearance of a product of 1 kb indicated excision of exon 3 (\(\Delta\)). PCR analysis with primers flanking the 3'-loxP site was used as loading control (Flox) (1: brain, 2: skeletal muscle, 3: heart, 4: liver, 5: spleen). C stands for PLRG-1\(^{\text{flox/flox}}\) mice (control)
As PLRG-1 deficiency induced apoptosis in both MEFs and heart tissue, I also examined the occurrence of apoptosis in the CNS of control and PLRG-1\(^{\Delta\text{CNS}}\) mice. Brains from control (PLRG-1\(^{\text{floxflo}}\)) and PLRG-1\(^{\Delta\text{CNS}}\) mice at postnatal day 3 were dissected and used for TUNEL analysis. Investigation of control and PLRG-1\(^{\Delta\text{CNS}}\) mice revealed a dramatic increase in the number of apoptotic neurons in the dentate gyrus of PLRG-1\(^{\Delta\text{CNS}}\) mice, coinciding with the region where Synapsin Cre mice have been shown to recombine most efficiently and where neurogenesis takes place (Fig 3.23) (Zhu et al., 2001). PLRG-1\(^{\Delta\text{CNS}}\) mice showed reduced agility, trembled and were not able to roll over when turned on their back.

![Figure 3.23: Immunohistochemical analysis of brains dissected from 3-day-old control and PLRG-1\(^{\Delta\text{CNS}}\) mice. Left and right panels: DAPI (nucleus) and TUNEL staining for control and KO of the same brain sections.](image)

As in PLRG-1-deficient MEFs and PLRG-1\(^{\Delta\text{mus}}\) mice, Western Blot analysis of brain tissue revealed increased p53 expression levels as well as enhanced p53 serine 15-phosphorylation in PLRG-1\(^{\Delta\text{CNS}}\) mice. Bax levels remained unaltered in brain cells, whereas PLRG-1\(^{\Delta\text{CNS}}\) mice also displayed a decrease in Bcl-2 expression (Fig. 3.24).
In summary, the absence of PLRG-1 in the CNS leads to massive apoptosis in the hippocampus. Thus, deficiency of PLRG-1 in the CNS evokes a similar apoptotic response to that observed in PLRG-1-deficient MEFs or cardiomyocytes.

3.16 Interaction of the nuclear CDC5L-PLRG-1 complex with the p53 phosphatase WIP1 is disrupted in the absence of PLRG-1

The previous studies with heart- and neuron-specific PLRG-1 knockout mice revealed massive apoptosis in the respective tissues, responsible for the premature death of the animals. Moreover, PLRG-1-deficient MEFs failed to enter S-phase upon serum stimulation and showed increased apoptosis as a result of enhanced p53 phosphorylation and stabilization. To understand the molecular basis of the PLRG-1 deficiency phenotype, the connection between PLRG-1 and p53 was further investigated.

Mass spectrometry and affinity purification analyses of proteins associated with CDC5L, the known interaction partner of PLRG-1, identified numerous spliceosomal components including ASF/SF2, hnRNP-G, SAP145, and U2A, as well as protein phosphatases such as PP1, PP2, and WIP1. Taking this into account, the question was addressed whether the CDC5L-PLRG-1 complex interacts with known p53 phosphatases, in particular with...
WIP1. To this end, nuclear extracts of wild type MEFs were immunoprecipitated with anti-WIP1 or an unrelated control followed by Western Blot analysis with anti-CDC5L. This analysis revealed the presence of CDC5L protein in WIP1 immunoprecipitates, but not in the unrelated controls (Fig. 3.25A), confirming the interaction of CDC5L and WIP1 in wild type control cells as previously reported (Ajuh 2000)

To determine whether the CDC5L-WIP1 interaction was also detectable in PLRG-1-deficient cells, co-immunoprecipitation experiments were performed using nuclear extracts from PLRG-1\textsuperscript{lox/lox} MEFs 48 h after Cre treatment. Surprisingly, this analysis revealed no immunoreactive CDC5L in WIP1 precipitates of PLRG-1-deficient nuclei (Fig. 3.25A).

To investigate whether this failure of CDC5L-binding to WIP1 is dependent on protein degradation or cytosolic translocation, CDC5L content was assessed in the respective fractions using Western Blot analysis. No difference in the total cellular content of CDC5L between wild type and PLRG-1-deficient MEFs was observed, but strikingly, CDC5L could only be detected in the cytosol of PLRG-1-deficient cells, whereas in control cells, CDC5L was mainly located in the nucleus (Fig. 3.25B). These data indicate that CDC5L interacts with WIP1 in the nucleus and that this complex fails to form in the absence of PLRG-1, which presumably results in cytosolic relocalization of CDC5L.
3.17 Rescue of the apoptotic PLRG-1 phenotype by knockdown of p53

To address whether stabilization of the p53 protein functionally accounts for the phenotype resulting from PLRG-1 deficiency, the effect of a downregulated p53 expression in PLRG-1-deficient cells was investigated. MEFs were either left untransfected or were transfected with siRNAs directed either against an unrelated sequence, against PLRG-1, against p53 or against PLRG-1 and p53. In this approach, I chose to knock down PLRG-1 expression using siRNAs, because HTNC-mediated deletion of PLRG-1 followed by siRNA transfection is toxic for the cells. Western Blot analyses revealed efficient siRNA-mediated silencing of PLRG-1 and p53 (Fig. 3.26).

Occurrence of apoptosis was determined performing TUNEL assays, and siRNA-mediated knockdown of PLRG-1 resulted in dramatically increased apoptosis in the presence of increased p53 expression and phosphorylation, as well as increased Bax and p21 expression, similar to the findings in PLRG-
$^{1}$flox/flox MEFs treated with HTNC (Fig. 3.26, Fig. 3.12). MEFs treated with p53 siRNA showed a decreased p53 expression, but no apparent phenotype and changes in Bax and p21 expression (Fig. 3.26). Cells treated with PLRG-1 along with p53 siRNA reversed the PLRG-1-deficient phenotype showing no apoptosis and restoring Bax and p21 expression levels to those found in cells either left untransfected or transfected with control siRNA (Fig. 3.26).

![Figure 3.26: Rescue of the apoptotic PLRG-1 phenotype by knockdown of p53](image)

Upper panel: Representative photomicrographs of TUNEL stained MEFs treated with the respective siRNAs. Lower panel: Percentage of TUNEL positive cells in MEFs treated with the respective siRNAs. Values represent mean ± SEM from three independent experiments (***p < 0.001).

(B) Western Blot analysis of MEFs treated with the respective siRNAs. Anti-β-actin was used to control for equal loading.
In collaboration with the group of Prof. Hammerschmidt (University of Heidelberg), the subject was addressed whether p53 regulation accounted also for the effect of PLRG-1 deficiency in vivo, using a morpholino-mediated knockdown of the PLRG-1 homolog in zebrafish (Danio rerio).

Its deduced amino acid sequence (Genbank accession number NM_213440) shows 77.9% identity to that of mouse plrg-1, indicating that this is a true ortholog. Whole-mount in situ hybridization analysis revealed ubiquitous distribution of zebrafish plrg-1 transcripts during all investigated developmental stages, i.e. from one-cell through to larval stages, indicating that the gene product is both maternally and zygotically derived (see http://zfin.org, gene expression).

Inactivation of zebrafish plrg-1 by Prof. Hammerschmidt’s group with an antisense morpholino-oligonucleotide (MO) targeting the plrg-1 translation initiation site led to dose-dependent severe and wide-spread apoptosis that was already apparent at early segmentation stages (12 h post-fertilization (hpf)).

Morphologically, the phenotype of MO-injected embryos was slightly stronger than that of naturally occurring zebrafish plrg-1 mutants (Amsterdam 2004) see http://zfin.org, mutants. This indicated that in mutants, defects are partly rescued by maternally supplied plrg-1 transcripts, which in this model are inactivated by MO injection. However, MO treatment did not affect maternally derived PLRG-1 protein, which would explain why the defects of zebrafish morphants develop later than those of PLRG-1-deficient mice. Importantly, concomitant inactivation of zebrafish p53 in plrg-1 morphants via co-injection of plrg-1 and p53 MOs (Langheinrich et al., 2002) led to a significant attenuation of apoptosis and morphological defects, adding further in vivo evidence that apoptosis resulting from plrg-1 deficiency is p53-dependent.

The data described above demonstrate that by deleting PLRG-1 along with p53 it is possible to rescue the apoptotic phenotype of PLRG-1 deficiency in MEFs. The knockdown of both proteins enables the cells to survive and normalizes Bax and p21 expression to wild type levels.

Taken together, it could be demonstrated that mouse PLRG-1 serves as an important nuclear regulator of complex formation between CDC5L and the p53 phosphatase WIP1, and thus is implicated in the control of G1/S-phase progression and apoptosis, thereby providing new insight into a novel
mechanism by which components of the spliceosome regulate cell cycle progression and apoptosis. Moreover, rescue of the PLRG-1-deficient phenotype in MEFs clearly establishes the causal role of p53 stabilization in the observed effects, further supporting the crucial role of the CDC5L-PLRG1 spliceosome complex for nuclear targeting of p53 phosphatase complexes.
4 Discussion

4.1 Essential role for PLRG-1 in the development of the preimplantation murine embryo

The results obtained in this thesis reveal a crucial role for PLRG-1 in the development of the preimplantation murine embryo. In fact, the loss of PLRG-1 constitutes such a severe impairment to the murine embryo that it leads to its death as early as embryonic day 1.5, a rarely described phenomenon in knockout mice. Apparently maternal PLRG-1 protein from the oocyte cannot compensate for the lack of PLRG-1 as early as the first day of embryogenesis, indicating a short half-life of PLRG-1 mRNA and protein. This notion is consistent with the fact that the amount of immunodetectable PLRG-1 in PLRG-1<sup>flox/flox</sup> MEFs is already largely reduced after overnight incubation with cell-permeable Cre. This finding is specific for mammals, because although inactivation of zebrafish <i>plrg-1</i> with antisense morpholino-oligonucleotides (MO) also leads to wide-spread apoptosis, defects of zebrafish morphants develop later than those of PLRG-1-deficient mice (unpublished data, Hammerschmidt et al.).

The mechanism, by which deletion of PLRG-1 ultimately results in embryonic lethality, is based on a failure in cell cycle progression. In yeast, the mutation of the PLRG-1 homologue YPL151c (Prp46) arrests cell proliferation causing a dual block in G/S- and M-phase progression (Albers et al., 2003; Sonnichsen et al., 2005). PLRG-1-deficient MEFs display a cell cycle arrest in G<sub>1</sub>/S phase and show an enlarged cell size. An increased cell size is typical for cells with a block in G<sub>1</sub>/S or G<sub>2</sub>/M transition due to cellular growth during gap phases (La Porta et al., 1998; Gandarillas et al., 2000). Enhanced stabilization of p53 ultimately leads to apoptosis of PLRG-1-deficient MEFs. Coinciding with the findings <i>in vitro</i>, analyses of a heart and a neuron-specific PLRG-1-deficient mouse strain display a similar severe apoptotic phenotype.

Taken together, the results gathered from experiments using PLRG-1-deficient MEFs and tissue-specific PLRG-1-deficient mouse models underline
the essential role of PLRG-1 in the regulation of cell proliferation and apoptosis independent from its postulated function in the regulation of pre-mRNA splicing.

4.2 Disruption of other splicing factors and their effects

To this date, only few knockout mice for components of the spliceosome have been described. Disruption of the splicing factor SRp20 was shown to result in early embryonic lethality. However, in contrast to PLRG-1-deficient embryos, SRp20-deficient embryos are still detectable at ED 3.5, despite the fact that immunoreactive SRp20 was already absent at the eight-cell stage (Jumaa et al., 1999). These data indicate that interference with splicing per se results in less dramatic effects on embryogenesis than disruption of PLRG-1. Similarly, disruption of the hnRNP C gene, encoding an essential component of hnRNP complexes involved in the regulation of pre-mRNA processing and export, results in embryonic lethality at ED 6.5 (Choi et al., 1986; Neubauer et al., 1998; Weighardt et al., 1996; Williamson et al., 2000). These previously described findings argue strongly for a specific additional or alternative role of PLRG-1 in cell cycle control and apoptosis rather than a general involvement in pre-mRNA processing and splicing.

This was confirmed by quantitative Realtime PCR using exon-spanning primers, which, surprisingly, excluded aberrant splicing in PLRG-1-deficient MEFs. This stands in contrast to a previously published role for PLRG-1 in splicing reactions (Ajuh et al., 2001; Ajuh and Lamond, 2003). However, all published splicing defects in mammals caused by PLRG-1 deficiency were postulated using an adeno-pre-mRNA-vector, an artificial splicing assay system. In contrast, the data obtained indicates no or merely a redundant role for PLRG-1 in splicing, showing that the functional role for PLRG-1 in mammals has diversified. In addition, the aberrant splicing for the TUB1 α-tubulin gene caused by the CDC5L mutation, the interaction partner of PLRG-1, did not occur in PLRG-1-deficient MEFs (Burns et al., 2002). PLRG-1-deleted cells showed an even higher expression of α-tubulin, which is consistent with the enlarged cell size.
The in vitro studies on PLRG-1 interaction partners demonstrate that mouse PLRG-1 serves as an important nuclear regulator of complex formation between CDC5L and the p53 phosphatase WIP1, and thus is implicated in the control of G1/S phase progression. This provides the first insight into a novel mechanism by which components of the spliceosome regulate cell cycle progression and apoptosis (Fig. 4.2). The results also highlight the possibility that mammalian and human PLRG-1 orthologues function analogously in this pathway, whereas their duplicated plant orthologues have probably diverged functionally throughout evolution.

### 4.3 Function of PLRG-1 orthologues

In contrast to eukaryotic species, which only have one PLRG-1 orthologue, Arabidopsis and other plants employ two PLRG-1 orthologues (Nemeth et al., 1998). Arabidopsis PRL1 and PRL2 exhibit a high degree of conservation in the C-terminal WD40 repeat domain, whereas their N-terminal sequences differ significantly (Nemeth et al., 1998). PRL1 has been initially identified as a transcriptional repressor in the regulation of glucose, sucrose and some plant hormone signaling pathways (Nemeth et al., 1998). Subsequent experiments showed that PRL1 interacts via its N-terminus with the α-subunits of Arabidopsis AMP-activated kinase orthologues AKIN10 and AKIN11 and inhibits the activity of these kinases in vitro (Bhalerao et al., 1999). The fact that no viable prl2 mutant could be isolated so far, suggests that PRL1 and PRL2 perform only partly overlapping functions and that, similarly to mouse PLRG-1, homozygous Arabidopsis PRL2 mutants are not viable (Csaba Koncz, unpublished). Given the fact that yeast and mammalian orthologues (Prp46p and PLRG-1) of Arabidopsis PRL proteins play a critical role in pre-mRNA splicing and that mouse and human PLRG-1 does not interact with AMPKs (Andrea Mesaros, unpublished), it is possible that plant members of the Pleiotropic Regulator WD40 domain family play somewhat divergent roles in signaling compared to other members of this family. This is consistent with the findings, that splicing is unaltered in PLRG-1-deficient MEFs.
In yeast, it has been demonstrated that the PLRG-1 orthologue Prp46p is essential for pre-mRNA splicing (Albers et al., 2003). Moreover, prp46 mutants exhibit a defect in cell cycle progression. While PLRG-1 deficiency in mouse leads to an arrest in G\(1\)/S phase transition (Fig. 3.11 and 12 in results), inactivation of yeast Prp46p results in impaired mitosis with a G\(2\)/M block (Albers et al., 2003). Biochemical and genetic studies demonstrate that Prp46p interacts with other components of the spliceosome, such as Prp45p, Prp19 (Pso4) and Cef1p/Cdc5p (Ohi and Gould, 2002). Mutations of these spliceosomal components result in pleiotropic defects, including temperature sensitivity, enhanced sensitivity to mutagens and radiation and accumulation of pre-mRNA (Ohi and Gould, 2002). Although the molecular mechanisms resulting in cell cycle defects as a consequence of deletion of spliceosomal components have not been fully characterized, previous experiments in yeast demonstrate that defective pre-mRNA splicing directly blocks mitosis. Thus, altered splicing of a single intron from TUB1 \(\alpha\)-tubulin gene, caused by the CDC5 mutation, results in the G\(2\)/M cell cycle defect in fission yeast (Burns et al., 2002). These data indicate that splicing of a critical component in cell cycle regulation may account for the defect present in mutants of yeast spliceosomal components. Nevertheless, deficiency for Prp17, another splicing factor, results in defects both in G\(1\)/S and G\(2\)/M progression, only the latter of which can be partially rescued by introducing an intronless tubulin gene (Chawla et al., 2003), indicating the presence of multiple pathways by which spliceosomal components can regulate cell cycle progression.

4.4 PLRG-1 in control of cell cycle and apoptosis

PLRG-1-deficient MEFs displayed a G\(1\)/S-phase block, resulting in decreased Cyclin D1 and Cyclin E expression and enhanced phosphorylated and thus stabilized p53 and increased p21 expression. Cyclin D1 expression is already reduced before serum stimulation, followed by a reduction in Cyclin E expression 6 h after serum stimulation of PLRG-1-deficient MEFs. This is consistent with findings that activated Cyclin D1/CDK4 complex
hyperphosphorylates Rb enabling E2F to act as a transcription factor (Schulze et al., 1994), which subsequently activates transcription of Cyclin E, forcing the progression into S-phase (Fig. 4.1).

The diminished expression of Cyclin D1 was not due to a general alteration in pre-mRNA splicing, as seen in Fig. 3.13, but rather as a result from enhanced p53 stabilization. As published by Guardavaccaro and colleagues, the p53-inducible gene PC3 induces the accumulation of hypophosphorylated Rb, thereby leading to an arrest in G1-phase. In addition, PC3 inhibits Cyclin D1 transcription, thus further contributing to the G1 arrest (Guardavaccaro et al., 2000). The findings of unaltered general pre-mRNA splicing were contradictory to data published by Ajuh et al., who postulated a role for PLRG-1 in pre-mRNA
Discussion

splicing in mammals (Ajuh et al., 2001; Ajuh and Lamond, 2003). As mentioned earlier, pre-mRNA splicing was investigated using an adeno-pre-mRNA-vector, a confirmed, yet artificial system.

Up to now, pre-mRNA splicing and expression of endogenous genes had not been studies in vivo. These data obtained is contradictory to published findings in yeast showing the importance for Prp46p (PLRG-1) in pre-mRNA splicing (Albers et al., 2003). Deletion of CDC5L in yeast leads to a G2/M block and the phenotype was rescued by introducing intronless α-tubulin cDNA into Saccharomyces cerevisiae, showing that removal of a single α-tubulin gene intron suppresses the cell cycle arrest phenotype (Burns et al., 2002). PLRG-1-deficient MEFs exhibit a 1.5fold increase in α-tubulin expression, indicating that PLRG-1 deficiency does not impair its expression. The enhanced expression of α-tubulin is consistent with the observation of the enlarged cell size of PLRG-1-deficient MEFs, indicating an enlarged cytoskeleton. The appearance of the knockout cells resembles the phenotype of senescent cells, which are characterized by enlargement and flattening of the cell (Bayreuther et al., 1992).

In terms of apoptosis, PLRG-1 deficiency resulted in enhanced p53 phosphorylation and stabilization, leading to a cell cycle block and apoptosis. This is consistent with findings, where wild type MEFs were irradiated with UV as an exogenous damage reagent. UV treatment led to enhanced p53 phosphorylation promoting p21 expression and to a decline in Bcl-2, resulting in apoptosis (Tomicic et al., 2005). PLRG-1-deficient MEFs and PLRG-1∆mus mice showed increased Bax levels, due to p53 stabilization, whereas PLRG-1∆CNS mice exhibited no difference in Bax expression compared to controls. Miyashita et al. showed that the tumour suppressor p53 is a direct transcriptional activator of the human Bax gene, further confirming the enhanced Bax expression observed in cell culture experiments and investigation of PLRG-1∆mus mice (Miyashita et al., 1995). However, Morris et al. could show p53-mediated Bax activation in neurons after DNA damage by translocation of Bax from the cytoplasm to the mitochondria and not by enhanced expression (Morris et al., 2001). Wang et al., showed a similar phenotype in terms of apoptosis in heart by knockdown of Tfam using the MCK-Cre mouse strain. The mice died 2-4 weeks after birth due to respiratory chain deficiency, dilated cardiomyopathy and atrioventricular heart conduction blocks (Wang et al., 1999). Contrary to our
findings that no deletion of PLRG-1 occurred in skeletal muscle using the MCK-Cre strain, they confirmed deletion of Tfam in this tissue. However, deletion of Tfam was investigated at day 32, a time point at which all PLRG-1\textsuperscript{∆mus} mice had already died. This indicates that MCK-Cre is potentially active from day 10 on, when considering the existence of PLRG-1 in skeletal muscle in the first days after birth.

The early postnatal death of the PLRG-1\textsuperscript{∆CNS} mice was a result of enhanced apoptosis in the dentate gyrus. Kim et al., showed that apoptosis in the dentate gyrus occurred in anorexia mice. These mice died during the third or fourth postnatal week, a similar strong phenotype as observed in PLRG-1\textsuperscript{∆CNS} mice. In addition, these mice displayed neurological defects, such as body tremors, a feature monitored in PLRG-1\textsuperscript{∆CNS} mice (Kim et al., 2001).

Taken together, these data indicate the importance of PLRG-1 in mitotic cells.

4.5 Impaired DNA damage repair as a consequence of PLRG-1 deficiency

PLRG-1-deficient MEFs exhibit no spontaneously detectable DNA double-strand breaks, but showed impaired DNA damage repair after UV treatment, indicating that PLRG-1 deficiency results in UV hypersensitivity. Mutation of ERCC1, a protein involved in nucleotide exchange repair, also results in UV hypersensitivity, supplying a possible connection to the DNA damage repair pathway (Johansson et al., 2004; Melton et al., 1998).

The enhanced appearance of γ-H2AX foci in PLRG-1-deficient MEFs indicates that these cells are sensitive to stalled replication forks without the ability to repair these. It was shown that pulse-field gel electrophoresis as a method for detection of DNA double-strand breaks reveals a sensitivity in detection of DNA double-strand breaks of a minimum of 100 lesions per cell (Johansson et al., 2004). The appearance of more than 100 γ-H2AX foci per cell (PLRG-1-deficient nuclei exhibit a complete accumulation of the foci), without detectable DNA double-strand breaks via pulse-field gel electrophoresis indicates that DNA lesions rather represent stalled replication forks than DNA
double-strand breaks. These findings were unexpected, because of previous data obtained that cells are arrested in the G₁-phase prior to the start of DNA replication in the S-phase. Possibly, when PLRG-1 is deleted in MEFs currently in the beginning of the S-phase, stalled replication forks occur leading to the observed phenotype. In addition, FACS analysis showed that the percentage of cells in S-phase was raised from 2.3 to 3.2% in PLRG-1-deficient MEFs indicating that these cells either do not show a complete deletion of PLRG-1 or a small proportion of cells enter the S-phase and directly stop progressing throughout the cell cycle due to spontaneously occurring DNA lesions. Replication forks, bulky DNA lesions or interstrand crosslinks are often spontaneously generated. Bulky DNA lesions are constantly produced by endogenously generated oxidative damage in mammalian cells (Melton et al., 2004). Furthermore, metabolic byproducts, such as malonyldialdehyde, cause interstrand crosslinks (Chaudhary et al., 1994) and DNA secondary structures, such as hairpins or G4-tetraplex structure at telomeres, cause stalled replication forks (Cromie et al., 2000; Samadashwily et al., 1997). Hence, naturally occurring stalled replication forks are common in mammalian cells and result in γ-H2AX foci, also observed in untreated PLRG-1<sup>floxfloxe</sup> MEFs. The increase in γ-H2AX foci in PLRG-1-deficient MEFs seems to occur from such lesions, because these cells did not exhibit enhanced DNA double-strand breaks. When encountering interstrand crosslinks, the cell uses the NER pathway followed by homologous recombination to repair this DNA damage (Niedernhofer et al., 2004). Because PLRG-1-deficient cells cannot progress in cell cycle, it seems impossible for these cells to repair these lesions.

ATR, a member of the PIKK-family, controls the integrity of DNA replication in unstressed cells (Shechter et al., 2004, Shechter et al., 2004). Thus, future experiments will have to address the role of ATR in mediating the PLRG-1-deficient phenotype.

The appearance of PLRG-1-deficient MEFs resembles that of senescent cells, displaying larger cell size and a flattened cell shape (Bayreuther et al., 1992). Another senescent-specific feature is an increase in telomere-dysfunction-induced foci, resulting in enhanced recruitment of γ-H2AX and other DNA damage response factors to telomeres (Takai et al., 2003). Herbig et al. could show that telomere shortening triggers senescence of human cells.
through a pathway involving p53 and p21, an upregulation of proteins also observed in PLRG-1-deficient MEFs, and resulting in a G₁ arrest (Herbig et al., 2004). However, deletion of PLRG-1 in MEFs showed this senescence-like phenotype for a maximum of 4-7 days due to p53-induced apoptosis. Whether PLRG-1 deficiency has an effect on senescent cells, despite their inability to divide and the accumulation of DNA double-strand breaks (Sedelnikova et al., 2004), remains unknown.

It remains elusive, whether PLRG-1 is recruited to DNA lesions with the Pso4-complex. Further investigation will show, if ATM or ATR plays the important role in phosphorylating p53 at serine 15 in this context.

4.6 Proposed model for PLRG-1, linking DNA repair, control of cell cycle progression and apoptosis via the Pso4-complex

This thesis demonstrated that murine PLRG-1 serves as an important regulator of complex formation between CDC5L and the p53 phosphatase WIP1 and is implicated in the control of G₁/S-phase progression and apoptosis; thereby, providing new insight into a novel mechanism by which members of the Pso4-complex are involved in the regulation of cell cycle progression, DNA damage repair and apoptosis (Fig. 4.2). This cell cycle defect is accompanied by increased p53 phosphorylation and expression, which results from failure of CDC5L to interact with the p53 phosphatase WIP1 in PLRG-1-deficient cells. Unlike the PLRG-1 mutants, WIP1-deficient mice are viable to adulthood, indicating that additional p53 phosphatases are associated with CDC5L (Anton et al., 2002). Thus, in addition to WIP1, PP-1 phosphatase was also detected in CDC5L-associated protein complexes by mass spectrometry. Furthermore, active PP1 co-purifies with CDC5L and CDC5L directly interacts with the PP1-binding nuclear-scaffold protein NIPP1 (Boudrez et al., 2000). Interestingly, disruption of the NIPP1 gene also results in early embryonic lethality although at a later stage (ED 6.5) (Van Eynde et al., 2004). Therefore, it is proposed that CDC5L interacts with multiple p53 phosphatases including WIP1 and PP-1α and that cytosolic relocation of CDC5L as a consequence of PLRG-1 deficiency
has a more severe effect than individual deletion or inhibition of these phosphatases. Moreover, rescue of the PLRG-1-deficient phenotype in both MEFs and zebrafish in vivo clearly establishes the causal role of p53 stabilization in the observed effects, thereby further supporting the crucial role of the CDC5L-PLRG-1 spliceosome complex for nuclear targeting of p53 phosphatase complexes.

The WRN/Pso4-CDC5L-PLRG-1 complex interaction is essential for uncoupling of DNA interstrand crosslinks (Zhang et al., 2005). The findings, that PLRG-1 deficiency results in enhanced appearance of γ-H2AX foci and impaired DNA damage repair, lead to the assumption that PLRG-1 is crucial for stabilizing the multiprotein-complex implicated in DNA damage repair. Therefore, these data extend the role of the Pso4-CDC5L-PLRG-1 complex beyond the regulation of pre-mRNA splicing to DNA repair (Zhang et al., 2005). Thus, direct integration of interstrand crosslink uncoupling in the regulation of p53 stability through Pso4-CDC5L-PLRG-1-regulated phosphorylation provides a new working model (Fig. 4.2). Namely, cell cycle arrest initiated upon stalled replication forks or double-strand break could be resolved by the final steps of interstrand crosslink uncoupling to signal successful repair to the cell and allow further cell cycle progression. In this model, DNA double-strand breaks as intermediates of interstrand crosslink (ICL) repair result in the activation of the ATM kinase family, stimulating p53 phosphorylation and stabilization. This subsequently leads to increased Cdk-inhibitor p21 expression and ultimately to stimulation of expression of the pro-apoptotic Bax protein. If ICL repair proceeds successfully, the Pso4-CDC5L-PLRG-1 complex recruited to the ICL site, promoting interaction of CDC5L with the p53 phosphatase, allows for dephosphorylation and subsequent degradation of p53. This stimulates re-entry into the cell cycle and inhibits apoptosis (Fig. 4.2).
Although in the present experiments, the role of Pso4-CDC5L-PLRG-1-mediated p53 regulation in ICL repair was not directly investigated, further studies are in progress to clarify the role of Pso4-CDC5L-PLRG-1-mediated p53 regulation in ICL repair.

This novel link between spliceosomal and DNA-repair components and the regulation of cell cycle progression and apoptosis appears particularly interesting as in many mammalian tumors CDC5L and/or PLRG-1 are overexpressed (Fenske et al., 2006; Geigl et al., 2004; Groenen et al., 1998). Hence, the interaction of overexpressed CDC5L with p53 phosphatases may provide a new mechanism for p53 suppression in tumorigenesis. Further characterization of the signaling network including additional partners of PLRG-
Discussion

1, CDC5L, and the p53 phosphatase WIP1 is therefore expected to help in further deciphering regulatory links between common components of splicing and DNA repair pathways and may yet uncover functions in malignant transformation.
Mammalian Pleiotropic Regulator PLRG-1 was initially identified as a component of the spliceosome and belongs to a highly conserved family of seven WD40 domain containing proteins in eukaryotes (Ajuh et al., 2000; Ajuh et al., 2001). Founding members of this WD40-repeat protein family, PRL1 and PRL2, were first identified by T-DNA tagging in Arabidopsis thaliana (Nemeth et al., 1998). Whereas in plants the PRL genes are uniquely duplicated, in yeast, C. elegans and mammals there are only single orthologues of the Pleiotropic Regulator family which play important roles in the control of cellular homeostasis by forming at least in mammals, a complex with Pso4 and the cell division and cycle 5 homolog (CDC5L), that regulates both pre-mRNA splicing and DNA repair.

To characterize the role of PLRG-1 in vivo, in the present study, I inactivated its gene both conventionally and conditionally in mice. Here, it is shown that inactivation of PLRG-1 results in embryonic lethality 1.5 days post-fertilization in mice, indicating a fundamental role for PLRG-1 in early cell cycle events. Studies on heart- and neuron-specific PLRG-1 knockout mice revealed that massive apoptosis was responsible for their premature death. Moreover, PLRG-1-deficient mouse embryonic fibroblasts (MEFs) fail to enter S-phase upon serum stimulation and show increased apoptosis resulting from enhanced p53 phosphorylation and stabilization. Interestingly, p53-phosphatase WIP1 was seen to interact with CDC5L in wild-type, but not in PLRG-1-deficient MEFs due to cytosolic translocation of CDC5L. p53 downregulation rescues lethality in PLRG-1-deficient MEFs, showing that apoptosis resulting from PLRG-1-deficiency is p53 dependent. Taken together, it is shown that the Pso4-CDC5L-PLRG-1 complex controls cell proliferation and apoptosis by novel integration of pre-mRNA splicing and DNA repair via a p53-phosphorylation-dependent pathway, thus providing the first evidence for Pso4-complex regulation of p53.
Zusammenfassung

6 Zusammenfassung


Um die Funktion von PLRG-1 in Säugetieren in vivo zu charakterisieren, habe ich im Rahmen der vorliegenden Arbeit das PLRG-1-Gen in Mäusen sowohl konventionell, als auch konditionell inaktiviert. Es konnte gezeigt werden, dass die Inaktivierung von PLRG-1 in Mäusen embryonale Lethalität an Tag 1,5 nach Befruchtung der Eizelle zur Folge hat, welches für eine fundamentale Rolle von PLRG-1 in der ersten Zellteilung spricht. Herz- und Neuron-spezifischen Knockout Mäuse weisen eine massive Apoptose in diesen Organen auf, welche zu deren frühzeitigem Tod führt. Außerdem verlieren PLRG-1-defiziente Mausembryofibroblasten (MEFs) die Fähigkeit, nach Serumstimulation in die S-Phase einzutreten und weisen eine erhöhte Apoptose auf, welche aus vermehrter p53 Phosphorylierung und Stabilisierung resultiert. Interessanterweise interagiert die p53-Phosphatase WIP1 mit CDC5L in Wildtypenzellen, nicht jedoch, aufgrund der cytosolischen Translokation von CDC5L, in PLRG-1-defizienten MEFs. Die Herunterregulierung von p53 rettet die Lethalität sowohl in PLRG-1 defizienten MEFs als auch in Zebrafisch in vivo, und verdeutlicht, dass die durch PLRG-1 Defizienz hervorgerufene Apoptose p53 abhängig ist. Zusammenfassend konnte gezeigt werden, dass der Pso4-CDC5L-PLRG-1 Komplex Zellproliferation und Apoptose, durch p53-Regulation kontrolliert.
7 Kurzzusammenfassung

8 References


Fulda, S., Meyer, E., Friesen, C., Susin, S. A., Kroemer, G., and Debatin, K. M.


References


References


Sanchez, Y., Wong, C., Thoma, R. S., Richman, R., Wu, Z., Piwnica-Worms,


References


mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81, 801-809.


Vialard, J. E., Gilbert, C. S., Green, C. M., and Lowndes, N. F. (1998). The budding yeast Rad9 checkpoint protein is subjected to Mec1/Tel1-dependent
hyperphosphorylation and interacts with Rad53 after DNA damage. Embo J 17, 5679-5688.


Acknowledgements

9 Acknowledgements

My sincere thanks to Prof. Dr. Jens Brüning for giving me the opportunity to join his research group, for supporting and giving me advice in all ways.

I want to thank Prof. Dr. Thomas Langer, Prof. Dr. Siegfried Roth and Dr. Ursula Lichtenberg for agreeing to form my thesis committee.

I want to thank my family and Tina Baumeister for their love and support.

I wish to express my gratefulness to Sigrid Irlenbusch for being a perfect technician and friend. I thank the lab 3.45 and Gabi for being a fruitful place to work in.

I would like to express my sincere gratitude to all the members of the Brüning lab for creating a friendly and productive environment.

In particular I thank, Béatrice Bailly-Maitre, Stephanie Baudler, Nadine Hövelmeyer, Linda Koch, and Thomas Wunderlich for critical proofreading the manuscript.

Furthermore I thank Christoph Göttlinger, Sonja Becker, Brigitte Hampel and Julia Baumgartl for technical assistance.

I thank Carsten Merkwirth and Dr. Paul Ajuh for supply of HTN-Cre protein and PLRG-1 antibody.

I thank Miriam Große Hovest and Tobias Heinen for technical advice in γ-H2AX staining and pulse-field gel electrophoresis.
10 Versicherung


Köln, im Mai 2007

André Kleinridders

Teilpublikationen

11 Lebenslauf

Persönliche Angaben:

Name: André Kleinridders
Adresse: Moerser Str. 144
47803 Krefeld
Telefon: 02151 20 63 30
Email: andrekleinridders@web.de
Geburtsort: Krefeld – Hüls
Familienstand: Ledig
Nationalität: Deutsch

Schulische Ausbildung:

1984 – 1988 Grundschule Kempenener Allee, Krefeld

Wehrdienst:

1997 – 1998 Wehrdienst bei der Luftwaffe der Bundeswehr

Akademische Ausbildung:

1998 – 2003 Studium der Biologie an der Mathematisch – Naturwissenschaftlichen Fakultät der Universität zu Köln
Lebenslauf

2002  
Diplomprüfungen  
Hauptfach: Genetik  
Nebenfächer: Biochemie & Pharmakologie

2002 – 2003  
Diplomarbeit am Institut für Genetik der Universität zu Köln zum Thema: „Inaktivierung des Maus PLRG-1-Gens“

Promotion:

Seit 07/2003  
Dissertation am Institut für Genetik der Universität zu Köln zum Thema: „Inactivation of Pleiotropic Regulator 1 reveals p53-dependent Control of Cell Proliferation and Apoptosis by the Pso4-complex“

Publikationen: